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L’encéphalopathie hypoxique-ischémique néonatale est une condition critique pouvant
survenir à la naissance, ainsi qu’une cause importante de mortalité et de morbidité
neurologique en lien avec des séquelles invalidantes à long-terme. Elle touche 1-2 pour 1000
naissances vivantes en Suisse. Considérant les importantes conséquences cliniques et le
manque de stratégies neuroprotectrices efficaces, il est urgent de mieux comprendre les
différents mécanismes de mort cellulaire impliqués ainsi que leurs interconnections, dans le
but de développer de nouvelles approches thérapeutiques. Les caractéristiques
morphologiques des trois différents mécanismes principaux de mort cellulaire peuvent toutes
être observées dans des modèles animaux de lésion cérébrale hypoxique-ischémique
périnatale : mort cellulaire nécrotique, apoptotique et autophagique. Ces différents types de
morts cellulaires sont le plus souvent retrouvés de manière combinée dans le même neurone
agonique. Dans cette revue, nous discutons les différents mécanismes de mort cellulaire
impliqués dans l’hypoxie-ischémie cérébrale néonatale, avec une attention particulière portée
à la manière dont l’autophagie pourrait être impliquée dans la mort neuronale. Nous nous
basons à la fois sur des modèles expérimentaux d’hypoxie-ischémie périnatale et d’accident
vasculaire cérébral ainsi que sur des études autoptiques menées sur des cerveaux de nouveau-
nés humains ayant souffert d’hypoxie-ischémie néonatale.
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a  b  s  t  r  a  c  t
Neonatal  hypoxic-ischemic  encephalopathy  is  a critical  cerebral  event  occurring  around  birth  with  high
mortality  and  neurological  morbidity  associated  with  long-term  invalidating  sequelae.  In  view of  the
great  clinical  importance  of this condition  and  the  lack  of very  efficacious  neuroprotective  strategies,  it
is urgent  to  better  understand  the different  cell  death  mechanisms  involved  with  the  ultimate  aim  of
developing  new  therapeutic  approaches.  The  morphological  features  of  three  different  cell  death  types
can  be observed  in  models  of  perinatal  cerebral  hypoxia-ischemia:  necrotic,  apoptotic  and  autophagic
cell  death.  They  may  be combined  in  the  same  dying  neuron.  In  the  present  review,  we discuss  the
different  cell  death  mechanisms  involved  in  neonatal  cerebral  hypoxia-ischemia  with  a  special  focus
on  how  autophagy  may  be involved  in neuronal  death,  based:  (1)  on  experimental  models  of  perinatal
hypoxia-ischemia  and  stroke,  and  (2) on the  brains  of  human  neonates  who  suffered  from  neonatal
hypoxia-ischemia.
©  2015  Elsevier  Ltd. All  rights  reserved.
1. Neonatal hypoxic-ischemic encephalopathy
Neonatal asphyxia is one of the most prominent long term
invalidating insults occurring around birth. The cerebral injury
after neonatal hypoxia-ischemia (HI) appears to be responsible for
nearly 25% of all cases of developmental disabilities in children
such as cerebral palsy, mental retardation, learning disturbances
and neurosensorial deficits (Vannucci and Hagberg, 2004). The
known etiologies are multiple intrapartum events including pla-
cental abruption, maternal infection, umbilical cord prolapse or
vasa praevia rupture (Rennie et al., 2008) all inducing an insufficient
supply of oxygen and blood to the central nervous system, thus
potentially leading to cerebral tissue lesions. The pathophysiologi-
cal mechanisms of perinatal stroke, as another prominent perinatal
cerebral pathology, are similar to those of neonatal asphyxia, but
in this brief review we  will mainly focus on the latter.
Abbreviations: AIF, apoptosis inducing factor; Atg, autophagy related genes;
HI,  hypoxia-ischemia; HIE, hypoxic-ischemic encephalopathy; Ka, kainate; LC-3,
microtubule-associated light chain 3 protein; LAMP1, light chain associated mem-
brane protein 1; NMDA, N-methyl-d-aspartate; ROS, reactive oxygen species; WT,
wild type:knot.
∗ Corresponding author.
E-mail address: anita.truttmann@chuv.ch (A.C. Truttmann).
A severe global asphyxia may  affect numerous brain regions,
especially the perirolandic cortex, basal ganglia, thalamus, hip-
pocampus and rarely the cerebral pons (Johnston et al., 2005).
The clinical cerebral entity observed is termed hypoxic-ischemic
encephalopathy (HIE), with loss of tonus and archaic reflexes,
epileptic seizures, diminished levels of consciousness and impaired
breathing (Ferriero, 2004).
To understand the different cellular mechanisms leading to the
neurological sequelae later in life, it is crucial to ask at least three
questions: why  does a neuron die after hypoxic-ischemic events,
when does it die and how or by which cell death mechanisms does
it die?
In the following paragraphs, we  will attempt to give partial
answers to these three questions, based on animal models of peri-
natal cerebral hypoxia-ischemia as well as human data and focusing
on autophagy-mediated cell death mechanisms.
2. Why  and when does a neuron die after
hypoxia-ischemia?
2.1. Pathophysiology
2.1.1. Primary versus secondary energy failure
The concept of the biphasic evolution of high energy phosphates
such as phosphocreatine and ATP after an hypoxic-ischemic event
http://dx.doi.org/10.1016/j.ijdevneu.2015.06.008
0736-5748/© 2015 Elsevier Ltd. All rights reserved.
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was developed in the late 1980s and consolidated in the early
1990s, opening the way for new protective approaches and defining
more precisely the therapeutical window, thought to be between
6 and 48 h according to the species and depth of asphyxia (Lorek
et al., 1994; Nedelcu et al., 1999; Thornton et al., 2012).
Primary energy failure takes place immediately after the
hypoxic event, very abruptly, and corresponds at the cellular level
to necrotic cell death, which is irreversible, and on MRI  is noted as
cytotoxic edema. This first energy decrease is thus hard to prevent
other than through optimizing the training and skills of the people
taking care of pregnant women and their newborns.
A second energy failure (associated with reperfusion injury)
starts after 24 h, with a peak around 48 h, after which the brain
energy level returns to near-normal values. This reperfusion stage
is associated with the production of toxic substances such as free
radicals, and the activation of multiple cascades and transcrip-
tion factors, with subsequent programmed cell death. On MRI, it
is also known as vasogenic edema (on diffusion-weighted imag-
ing) (Vannucci and Hagberg, 2004; Yager and Ashwal, 2009). In
attempts at neuroprotection, it is the reperfusion injury phase that
is the most targeted nowadays.
Since 2006, moderate hypothermia has been acknowledged as
evidence based medicine for application in moderate to severe
cerebral hypoxic-ischemic encephalopathy (HIE), and is now
widely used as a therapeutic approach (Edwards et al., 2010;
Gluckman et al., 2005; Gunn, 2000; Xiong et al., 2013) in the first
72 h after the event. While mortality was reduced in several large
studies (Azzopardi et al., 2014; Gluckman et al., 2005; Shankaran
et al., 2005), the neurological outcome benefit at 18 months was
lost at 6–7 years of age in one study and maintained in another
study (Shankaran et al., 2012).
2.1.2. Excitotoxicity
One of the central deleterious processes implicated in neuronal
damage after hypoxic-ischemic brain injuries is excitotoxicity which
is also involved in other cerebral pathologies such as epilepsy,
traumatic brain injuries or neurodegenerative diseases (Sattler
and Tymianski, 2000). It represents an excessive and prolonged
activation of excitatory amino acid receptors, especially those
for glutamate and in particular N-methyl-d-aspartate (NMDA)
receptors (Olney and Ho, 1970; Vannucci and Hagberg, 2004).
Failure in glutamate reuptake combined with excessive release
at the synaptic level lead to glutamate accumulation, overacti-
vation of glutamate receptors and massive entry of calcium (Lau
and Tymianski, 2010). The increased intracellular calcium concen-
tration triggers the activation of numerous downstream enzymes
(proteases, lipases, kinases. . .)  leading to cell damage by numerous
mechanisms including oxygen and nitrogen reactive species forma-
tion, membrane destruction, impairment of organelles and/or DNA
damages (Sattler and Tymianski, 2000).
The immature brain is particularly susceptible to excitotoxi-
city. During brain development NMDA receptors show a higher
density (McDonald et al., 1988) and are more readily activated
due to their higher permeability to calcium, greater responsive-
ness to glycine activation and lower sensitivity to Mg2+ blockade
in comparison to mature receptors (Gurd et al., 2002; Johnston
et al., 2005). This is crucial for synaptic plasticity and brain matura-
tion (Herlenius and Lagercrantz, 2001), but renders neurons more
vulnerable to excitotoxic stimuli. Moreover !-Amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) receptors are usually
impermeable to calcium, except when the GluR2 subunit is lacking,
which is mainly the case in immature brains. In both white and gray
matter, the periods of high GluR2 deficiency correspond to those
of regional susceptibility to hypoxic/ischemic injury in young rats
(Talos et al., 2006).
2.1.3. Reactive oxygen species (ROS)
Oxidative stress is another important damaging mechanism
leading to HI cerebral damage. It is closely related to excitotoxi-
city since excessive calcium influx can activate different enzymes
involved in ROS production such as neuronal nitric oxide synthase
or xanthine and NADPH oxidases. Dysfunction in mitochondrial
oxidative phosphorylation is a main cause of excessive formation
of free radicals (superoxide (O2−), hydrogen peroxide (H2O2), nitric
oxide (NO), hydroxyl radical (OH−) and peroxynitrite (NOO−)). ROS
are extremely toxic for the surviving cells since natural defense
systems are overwhelmed in HI conditions. ROS accumulation
triggers a cascade of cytotoxic events including protein nitrosy-
lation and oxidation, lipid peroxidation, membrane destruction
and DNA damage. It increases blood-brain-barrier permeability
(Baburamani et al., 2012; Pun et al., 2009) and activates inflam-
mation through the release of cytokines and chemokines (from
reactive astrocytes, activated microglia, neurons and endothelial
cells) that are involved in leukocyte recruitment. Oxidative stress
can lead to a massive secondary phase of tissue loss over the next
few days or even weeks after the primary injury (Ferriero, 2001).
Immature brains are particularly sensitive to oxidative stress, as
their antioxidant enzymatic capacities are lower than in adults and
as they have higher concentrations of free iron and unsaturated
fatty acids (Haynes et al., 2005; Vannucci and Hagberg, 2004).
2.1.4. Inflammation
Finally a third central factor that can play a role in long
term cerebral injury of the newborn is inflammation, i.e. mainly
microglial activation and leukocyte recruitment. It acts via
cytokines like TNF-!, IL-1" and IL-6 that are able to act locally but
also to spread the inflammatory reaction and thus increase the vul-
nerability of the rest of the brain tissue (Fleiss et al., 2015; Hagberg
et al., 2015). This thematic is discussed elsewhere in this issue and
is therefore not further developed here.
3. How does a neuron die after perinatal asphyxia?
3.1. Necrosis and apoptosis in neonatal HI
The morphological features of three different cell death types
can be observed following HI, even in the same dying neuron
(Northington et al., 2011): necrotic, apoptotic and autophagic cell
death (Fig. 1). Whereas apoptotic and necrotic cell death are well-
known cell death types that have been the most studied in perinatal
HI models (Northington et al., 2011), the importance of autophagy-
mediated cell death is a recent field of interest that is starting to
be elucidated (Ginet et al., 2014a; Ginet et al., 2014b; Puyal et al.,
2013).
3.2. Necrotic cell death
Necrotic cell death (or type 3) represents the earliest death
mechanism in the context of cerebral ischemia and excitotoxic-
ity since it is associated with the initial massive influx of calcium
into the neuron’s cytoplasm (Northington et al., 2011). Necrotic
cell death, which is characterized by a cellular swelling that can
lead to cell lysis, is already seen as early as 30 min after the insult.
It is triggered by abrupt energy failure with notably ATP deple-
tion. No specific markers of necrotic cell death are known, but
calcium-dependent activation of calpains is suggestive of it and
can be detected through the presence of calpain-dependent !-
fodrin fragments around 150 kDa in immunoblot (Neumar et al.,
2001). Electron microscopy is the only definitive method for diag-
nosing necrotic death, whose specific features include organelle
dilatation, vacuolization of the cytoplasm and nuclear fragmenta-
tion (Clarke, 1990; Puyal et al., 2013). Necrotic cell death plays a
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Fig. 1. Main morphological features of the 3 different cell death pathways: apoptosis, necrosis and autophagic cell death. (A) Apoptosis is characterized by nuclear and
chromatin condensation, cytoplasmic shrinkage and the presence of apoptotic bodies. Necrotic cell death shows swollen organelles (mitochondria, endoplasmic reticulum. . .)
and  lysis of the plasma membrane. Autophagic cell death displays numerous autophagosomes and autolysosomes, and often also endosomes and empty vacuoles. (B-D)
Electron micrographs illustrate the different cell death features that could be observed in dying neurons after neonatal HI (p7 rat). (B) Dying neuron in the thalamus at
24  h after neonatal HI showing mixed features of both apoptosis and enhanced autophagy. (C) Dying neuron in the CA3 region of the hippocampus at 24 h after neonatal HI
displaying strong autophagic features. (D) Dying neuron in the CA1 of the hippocampus at 24 h after neonatal HI with mixed morphological characteristics of apoptosis and
necrosis. *: autophagosome; #: autolysosome. N: nucleus; ER: endoplasmic reticulum; M: mitochondrion; AP: autophagosome; AL: autolysosome; EV: empty vacuole; L:
lysosome. Scale bars: 1 #m.
central role in acute brain lesions, as has been shown in several
adult models (Mehta et al., 2007), but also in models of neona-
tal HI (Carloni et al., 2007; Nakajima et al., 2000; Northington
et al., 2001). Some post-mortem neuropathological studies have
indicated the presence of necrotic-like cells in human perinatal
brain injuries (Northington et al., 2011; Takizawa et al., 2006).
Since necrosis occurs at the very beginning of the hypoxic-ischemic
event, when the levels of oxygen and nutrients fall below critical
values, it might be thought an unpromising target for neuropro-
tection as the lesion could often be constituted by the time the
diagnosis is made. However, even with necrosis, the therapeutic
window seems to be relatively large in immature brains (up to 6 h),
thus the clinical potential of necrosis inhibition remains interest-
ing (Degterev et al., 2005; Markgraf et al., 1998; Mehta et al., 2007;
Puyal et al., 2013). While the original descriptions of necrosis in the
1980s pointed to an unprogrammed and passive process, active
mechanisms are now known to be involved in many cases of it,
including hypoxic and/or ischemic neurons, whose necrotic death
pathways can involve calpains (Yamashima et al., 2003), c-jun N-
terminal kinases (Arthur et al., 2007) or even caspases (Niquet et al.,
2003). One of the best studied form of active (regulated) necrosis
is necroptosis (Yuan and Kroemer, 2010), which has been shown
to occur in neonatal HI (Thornton et al., 2012). The molecular path-
ways mediating necroptosis can be triggered by death receptors
whose ligands can also be involved in apoptosis (such as TNF!, FasL
and TRAIL) (Vandenabeele et al., 2010; Yuan and Kroemer, 2010)
and by toll-like receptors (Galluzzi et al., 2014). After death recep-
tor stimulation and when caspase-8 is inhibited, reduced or absent,
RIPK1 and 3 (receptor-interacting protein kinase) and MLKL (mixed
lineage kinase domain-like) form the necrosome, a signaling com-
plex mediating necroptosis (Galluzzi et al., 2014; Linkermann and
Green, 2014). The regulated forms of necrosis seem to be relatively
delayed and could represent an interesting therapeutic target. Neu-
roprotection against perinatal HI has been achieved with inhibitors
of calpains (Kawamura et al., 2005) or of necroptosis up to 6 h after
the injury (Degterev et al., 2005; Northington et al., 2011).
3.3. Apoptosis
Apoptotic features are often observed in excitotoxic injuries,
such as cerebral ischemia and neonatal asphyxia (Northington et al.,
2011; Puyal et al., 2013), including in human HIE (Northington et al.,
2011; Taniguchi et al., 2007). As has been well described, apoptosis
is a programmed and delayed death mechanism that can be medi-
ated by either of two  intracellular signaling pathways, the intrinsic
and the extrinsic pathways.
a The intrinsic pathway is mediated by a release of apopto-
genic factors (cytochrome-c, Smac/Diablo, apoptosis inducing
factor (AIF), endonuclease G (endoG), Omi/HtrA2) from the
mitochondria after membrane permeabilization that trigger
caspase-dependent and -independent cell death processes. Bcl-
2 family proteins including the pro-apoptotic Bax, Bim and Bak
and the anti-apoptotic Bcl-2, Bcl-XL and Mcl-1 are implicated
in the regulation of mitochondrial membrane permeabilization
(Thornton et al., 2012). Cytochrome-c release will result in initia-
tor caspase-9 activation that activates the main effector caspases,
caspase-3, -6 and -7 (Broughton et al., 2009; Fan et al., 2005;
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Thornton et al., 2012). Smac/Diablo and Omi/HtrrA2 contribute
to caspases activation by preventing IAP (Inhibitor of Apoptosis
Protein) family of proteins to interact and to inhibit effector cas-
pases. Other molecules released from mitochondria can activate
caspase-independent pathways; these include AIF (apoptosis
inducing factor) and the endonuclease endoG, which are both
translocated to the nucleus and mediate DNA damage.
b The extrinsic pathway depends on the activation of death
receptors whose ligands include cytokines such as tumor necro-
sis factor-alpha (TNF!). It involves the action of the initiator
caspases-8 and -10 that activate effector caspases directly and/or
by interacting with the intrinsic pathway after the caspase-
mediated cleavage of Bid (a BH3-only Bcl-2 family member) and
subsequent mitochondrial membrane permeabilization.
All of these apoptotic mechanisms are known to be more promi-
nent in immature brains than in adult ones (Zhu et al., 2005). After
HI and especially in immature brains, the apoptotic pathways are
strongly activated and seem to be involved especially in the sec-
ondary phase of the insult described under point 2.1. (Nakajima
et al., 2000; Northington et al., 2011). Apoptosis thus represents a
potential target for neuroprotective interventions within the ther-
apeutic window. Indeed several experimental studies found that
treatment with pan-caspase inhibitors or specific ones led to a
reduction of the lesion and a better neurologic outcome in both
adult cerebral ischemia (Akpan and Troy, 2013; Mehta et al., 2007)
and neonatal HI (Adachi et al., 2001; Carlsson et al., 2011; Chauvier
et al., 2011; Feng et al., 2003) models. However, some of these
authors applied the anti-apoptotic drugs before the injury, which is
clinically less relevant, and different models of perinatal HI showed
controversial results (Gill et al., 2002; Joly et al., 2004; Koike et al.,
2008; Puyal et al., 2009). The neuroprotection afforded by caspase
inhibitors depends on the type and severity of the ischemic insult,
as also shown in adult models (Li et al., 2000) and caspase inhibitors
remain rather unspecific, which restricts the interpretation of the
results (Northington et al., 2011). Until now, no caspase inhibitor
has been tested in a clinical trial.
4. Autophagy and cell death
We  will first briefly introduce the molecular mechanisms
involved in autophagy and then discuss the role of autophagy in
neuronal death specifically in neonatal cerebral HI (see Section 5).
4.1. Overview of the molecular mechanisms of autophagy
Autophagy is an essential intracellular catabolic pathway that
functions in parallel with the ubiquitine-proteasome system (Feng
et al., 2014). There are three types of autophagy that all lead to
degradation in lysosomes and recycling (Feng et al., 2014; He
and Klionsky, 2009). (1) Microautophagy implicates the engulf-
ment of part of the cytoplasm directly by the lysosomal membrane.
(2) Chaperon-mediated autophagy is a more specific mechanism
that targets proteins bearing a precise amino-acid sequence in
order to target them directly to the lysosome. (3) Macroau-
tophagy (hereafter called autophagy) involves the participation of
an intermediate multimembranous compartment, the autophago-
some, which then fuses with a lysosome for degradation of its
content. During autophagosome formation, part of the cytoso-
plasm is engulfed, containing long-lived proteins and/or defective
organelles (mitochondria, endoplasmic reticulum, etc). Autophagy
is not as nonspecific as it was originally thought, since some pro-
teins on the autophagosomal membrane (such as SQSTM1/p62,
NBR1, optineurin. . .)  serve as adaptor proteins and target some
ubiquitinated substrates including mitochondria (mitophagy) or
misfolded proteins (Johansen and Lamark, 2011).
Autophagy can be divided into three main steps: nucleation
(induction), autophagosome formation (elongation, incurvation, clo-
sure) and maturation (fusion with a lysosome and formation of
an autolysosome) (Feng et al., 2014; He and Klionsky, 2009). An
overview of the molecular mechanisms is described in Figure 2.
Over 35 autophagic genes (named Atg: autophagic related genes)
have been discovered in yeast and most of them have homologues
in mammals.
4.1.1. Nucleation (induction)
This first step is the formation of the pre-autophagosomal mem-
brane (also called phagophore or isolation membrane), which can
be derived from different organelles (mitochondria, endoplasmic
reticulum and/or Golgi apparatus) and possibly from the plasma
membrane. The pre-autophagosomal membrane serves as a plat-
form for recruiting most of the Atg proteins necessary to the
formation of an autophagosome. Its isolation can be induced in
different conditions including under stress stimuli such as depri-
vation of nutrients/energy (Hosokawa et al., 2009), hypoxia/ROS
exposure (Chen et al., 2009; Scherz-Shouval et al., 2007) or intra-
cellular calcium increase (Gao et al., 2008; Hoyer-Hansen et al.,
2007). Among the downstream molecular regulators, the ser-
ine/threonine kinase mTor (mammalian target of rapamycin) is
a central player and its inhibition (e.g. by rapamycin) activates
autophagy. Complex molecular mechanisms involving interactions
between several Atg proteins are implicated in autophagy. Briefly,
the ULK1/2 (mammalian homolog of Atg1) complex, whose acti-
vation depends on mTor inhibition and AMPK phosphorylation
(Shang and Wang, 2011), plays an important role in autophagy
induction and probably in Atg protein recruitment. The class
III PI3K/Beclin1 (Atg6) complex produces phosphatidylinositol 3-
phosphate (PI3P) favoring Atg protein recruitment especially when
the complex contains Atg14L. It can also contain UVRAG, which is
important for autophagosomal membrane deformation and curva-
tion (Itakura et al., 2008).
4.1.2. Autophagosome formation
The autophagosome formation involves the elongation and
incurvation of the pre-autophagosomal membrane followed by
its closure to form the double-membraned autophagosome. The
ubiquitin-like conjugation system of Atg12-Atg5-Atg16L, whose
formation depends on Atg7 and Atg10, is important for the elon-
gation process and for the recruitment and formation of a second
ubiquitin-like conjugation system containing a microtubule-
associated light chain 3 protein (LC3) (Fujita et al., 2008). This
LC3 (mammalian homolog of Atg8) conjugation system acts on the
lengthening and closure of the autophagosome (Nakatogawa et al.,
2007; Sou et al., 2008). Similarly to ubiquitination, the cytosolic
Atg4-dependent cleaved form of LC3 (LC3-I form) is conjugated
by Atg7 and Atg3 to phosphatidylethanolamine (PE), an abundant
membrane phospholipid, that allows LC3 to be incorporated into
the autophagosomal membrane (LC3-II form) (Geng and Klionsky,
2008).
4.1.3. Autophagosome maturation
Whereas most of the known Atg proteins are implicated in the
early phases of autophagy, a few of them have been shown to act
in autophagosome maturation. Since autophagosomes sometimes
fuse with endosomal compartments (early endosomes, multivesic-
ular bodies, late endosomes) prior to their fusion with a lysosome
(Simonsen and Tooze, 2009), some endocytic proteins (Rab, COPs,
ESCRT, LAMP and SNARE proteins) occur in autophagosomal mem-
branes and are involved in their maturation (Mehrpour et al.,
2010). The resulting acidification allows lysosomal enzymes (such
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Fig. 2. Overview of the main molecular pathways involved in macroautophagy. This scheme highlights the main markers that can be used in vivo to monitor autophagy. First
the  nucleation is induced by the complex Beclin-1(Atg6)/PI3K-III. The progress of the incurvation and elongation phase is notably controlled by LC3-II (Atg8) that determines
the  sizes of the autophagosomes. The transformation of the cytosolic LC3-I into the membrane-bound form LC3-II is mediated by different complexes such as Atg7 or
Atg5/Atg12. The compartment is then acidified and hydrolases such as cathepsins are recruited by fusion with a lysosome. Monodansylcadaverine (MDC), an acidotropic dye,
is  incorporated into acidic endosomes, lysosomes and autophagosomes and can be used as a marker of late autophagosomes.
as cathepsins, acid phosphatases or "-hexosaminidase) to degrade
and recycle the autophagosome content.
In order to demonstrate that autophagy is enhanced, it is impor-
tant to investigate the whole autophagic pathway, not only the
increase in autophagosomal markers such as LC3-positive dots in
immunohistochemistry and LC3-II level in immunoblots. Increased
autophagic degradation must also be shown since an accumula-
tion of autophagosomes might also be due to a defect in fusion
with lysosomes. For this reason, it is important to obtain evi-
dence for an increase in autophagic flux. To demonstrate increased
degradation in vivo is often challenging, but possible approaches
include: measuring the expression level of p62/SQSTM1, a long-
lived protein preferentially degraded by autophagy, evaluating
lysosomal enzyme activities (such as acid phosphatase), quantify-
ing the numbers and sizes of lysosomes (labelled with MDC, LAMP1,
cathepsins.  . .),  using lysosomal enzyme inhibitors or measuring
the expression of an autophagy flux reporter such as Cherry-GFP-
LC3 (Castillo et al., 2013; Puyal et al., 2013).
4.2. Dual role of autophagy
As mentioned above autophagy is a very complex molecular
mechanism that plays an important role in physiological and vital
functions including cellular homeostasis, and cell growth and dif-
ferentiation during the developmental period. Whereas a basal
level of autophagy is essential for the well-being of cells especially
neurons, its induction can lead to opposite effects depending on the
level of activation, the stimulus and the cell type (Wang et al., 2008).
The best-known role of enhanced autophagy is a protective reac-
tion to promote cell survival by providing an alternative source of
energy in cells deprived of nutrients. It also promotes survival by its
capacity to eliminate toxic metabolites or intracellular pathogens
(He and Klionsky, 2009; Levine and Klionsky, 2004; Uchiyama et al.,
2008). However, in pathological situations autophagy can also pro-
mote cell death (see Section 4.3) (Clarke and Puyal, 2012; Edinger
and Thompson, 2004; Galluzzi et al., 2007; Lockshin and Zakeri,
2004; Maiuri et al., 2007b; Northington et al., 2011).
This dual role of autophagy is particularly important in neurons.
In the central nervous system, an excessively low basal autophagic
activity leading to decreased turnover of proteins is associated with
the development of neurodegenerative diseases (Komatsu et al.,
2006; Puyal et al., 2012). In contrast, excessive activity of autophagy
has been involved in cell death occurring naturally during devel-
opmental morphogenesis (Boland and Nixon, 2006) or in acute
neurological disorders like cerebral HI (Ginet et al., 2014b; Liu and
Levine, 2015; Koike et al., 2008; Puyal and Clarke, 2009; Xing et al.,
2012).
4.3. Autophagy in cell death
The life promoting roles of autophagy are well known and
accepted but a consensus about its pro-death roles has been hard
to find. An increase in autophagy in dying cells could be interpreted
as a last attempt for survival. Ambiguities due to the dual role of
autophagy (see above) and inconsistent use of the term “autophagic
cell death” have fueled the controversy (Clarke and Puyal, 2012;
Kroemer and Levine, 2008; Yuan and Kroemer, 2010). The discovery
of atg genes and the possibility of manipulating them (by knock-
out or knockdown) strongly contributed to determining specifically
the roles of autophagy, and this has led to evidence that autophagy
can be involved in cell death in one of two ways: as a trigger lead-
ing to apoptotic or necrotic cell death (autophagy-mediated cell
death), or less frequently, as an independent molecular mecha-
nism of cell death morphologically different from apoptosis and
necrosis (autophagic cell death or type 2). In this latter case, the
autophagy seems to be abnormally enhanced, leading to degra-
dation of important parts of the cell or even its nucleus (Clarke,
1990). Enhanced autophagy can be considered as an autonomous
cell death pathway if its inhibition reduces or delays the cell death
in the absence of signs of apoptosis or necrosis (Clarke and Puyal,
2012; Puyal et al., 2013). To date, whereas autophagy-mediated
cell death and autophagic cell death could easily be recognized
by using morphological criteria, the molecular pathways trigger-
ing both are poorly understood. Beside the fact that the autophagic
flux should be increased in both cases, it is not clear whether
similar or different Atg–Atg protein interactions are involved. It
remains essential to elucidate which molecular mechanisms can
shift autophagic machinery towards one of these two  cell death
pathways. However, it has been shown recently that cardiac gly-
cosides, known inhibitors of Na+/K+-ATPase, are able to prevent a
form of autophagic cell death called autosis both in vitro and in vivo
(Liu et al., 2013).
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Fig. 3. Interconnections between cell death mechanisms in neonatal cerebral HI.
An important difficulty is that autophagy-mediated cell death
often involves mixed features of autophagy and apoptosis/necrosis.
While crosstalk between necrosis and apoptosis exists (Galluzzi
et al., 2007; Northington et al., 2011), there is also evidence that
autophagy interacts with both of them (see Fig. 3). In some spe-
cific situations, as when cells are unable to perform apoptosis,
autophagy can promote death by necrosis (Ullman et al., 2008).
In excitotoxic and hypoxic-ischemic conditions, mixed forms of
cell death sharing autophagic and apoptotic features are more
often observed than pure autophagic cell death (see Section 5.2).
This can be partly explained by the fact that the autophagic
and apoptotic pathways share numerous common mediators and
molecular interconnections, creating a complex cross-talk. Some
autophagic proteins (Beclin1, Atg5, Atg4D, Atg1, Atg7. . .)  and apop-
totic molecules (Bcl-2, Flip proteins, Puma, Bax, p53, FoxO1.  . .)
have been shown to be implicated in the regulation of both
autophagy and apoptosis (Delgado et al., 2014; Marino et al., 2014;
Nikoletopoulou et al., 2013). One of the best known regulatory
interconnections is the formation of complexes between the anti-
apoptotic proteins Bcl-2, Bcl-XL or Mcl-1 with the autophagic
protein Beclin1, which inhibit autophagy by sequestering Beclin1.
Beclin1 release from these complexes by competitive interaction
with different pro-apoptotic BH3-only proteins such as Bax, Bim,
Nip3, Nix, Noxa and Puma promotes autophagy (Maiuri et al.,
2007a). Among other examples, the protein p53, a strong apopto-
sis inducer, is able to regulate autophagy (Tasdemir et al., 2008),
whereas it has been proposed that Atg7 can affect p53 activity (Lee
et al., 2012). It has also been suggested that autophagosomal mem-
branes can serve as a platform for caspase-8 activation (Young et al.,
2012).
5. Autophagy mediated cell death in neonatal HI
It is now commonly accepted that autophagy is enhanced in
dying neurons in both in vitro (Borsello et al., 2003; Dong et al.,
2012; Matyja et al., 2005; Sadasivan et al., 2010), and in vivo mod-
els of excitotoxicity, including intracerebral kainate (Ka) injection
(Chang et al., 2012; Shacka et al., 2007; Wang et al., 2006; Wang
et al., 2008) as well as in adult models (Adhami et al., 2006; Cui et al.,
2012; Degterev et al., 2005; Nitatori et al., 1995; Tian et al., 2010;
Xu et al., 2013) and in models of perinatal cerebral HI (Ginet et al.,
2009). However, as discussed above (see Section 4.3), the functional
role of enhanced neuronal autophagy remains a subject of debate.
Part of the problem is that autophagic flux is rarely correctly exam-
ined and/or that the role of autophagy is deduced from the use
of pharmacological inhibitors with often questionable specificity
(Klionsky, 2012).
5.1. Lessons from in vitro studies
We  here highlight briefly some important insights from in vitro
studies in order to give a complementary view of the role
that autophagy can play in hypoxic/excitotoxic conditions before
addressing the subject in more relevant in vivo models in which
the study of autophagic flux is more difficult (see Sectiont 5.2 and
Table 1).
Oxygen-glucose deprivation (OGD) and exposure to an excito-
toxin (NMDA, glutamate, Ka), are the most widely used in vitro
models of cerebral HI. In both models, increased autophagosome
presence has been observed (Borsello et al., 2003; Dong et al., 2012;
Shi et al., 2012). Borsello et al. observed the appearance of numer-
ous double membrane vacuoles and an increase in acid phosphatase
in the same dying neurons in organotypic hippocampal cultures of
P5 rats exposed to NMDA, suggesting an increased autophagic flux
(Borsello et al., 2003).
Concerning the functional role of enhanced autophagy in in vitro
models, there have been discrepancies between studies arguing for
a protective (Kulbe et al., 2014; Perez-Carrion et al., 2012; Zhang
et al., 2013) or deleterious (Dong et al., 2012; Ginet et al., 2014b;
Kim et al., 2009; Kubota et al., 2010; Meloni et al., 2011; Puyal et al.,
2013) effect of enhanced autophagy. However, very few investi-
gated the autophagic flux or used genetic methods to inhibit or
enhance autophagy. Other factors that may  have contributed to
these discrepancies are differences in the time points assessed, the
stimuli used, the cell types (primary neuronal cultures versus neu-
ronal cell lines), the culture conditions and the dose and specificity
of the pharmacological inhibitors/inducers of autophagy. As an in
vitro model of cerebral HI, our group developed a model involv-
ing the cytotoxic combination of Ka and hypoxia (KaHx) in primary
cortical neurons cultures (Ginet et al., 2014b). We  demonstrated
that neuronal death occurs in the presence of enhanced autophagic
flux by different methods (enhanced SQSTM1/p62 degradation,
increased LC3-II levels in the presence of lysosomal inhibitors
and increased autophagosome maturation shown using an RFP-
GFP-LC3 reporter). We  also demonstrated that KaHx-enhanced
autophagy was involved in neuronal death since inhibition of
autophagy, either by pharmacological inhibitors (3-methyladenine
or pepstatinA/E64) or by silencing of Atg7 or Beclin1, was neuro-
protective, whereas overexpression of Atg7 or Beclin1 increased
the vulnerability of the neurons to KaHx.
5.2. Hypoxia-ischemia and autophagy in vivo
As research on in vivo models of adult focal cerebral ischemia
had shown enhanced autophagy in the affected neurons (Adhami
et al., 2006; Cui et al., 2012; Degterev et al., 2005; Nitatori et al.,
1995; Rami et al., 2008; Tian et al., 2010; Xu et al., 2013), this
question was also addressed in less mature brains. In the field
of perinatal brain lesions, different animal models have been
developed in order to define the molecular mechanisms impli-
cated in hypoxic-ischemic brain lesions. Many of the studies were
performed on rodents, with the most widely used and well charac-
terized model being a unilateral common carotid artery occlusion
followed by a period of global hypoxia (Rice et al., 1981) (the
Rice-Vannucci model). To our knowledge, only rodent models have
been used until now to study the autophagic pathways in neonatal
brain injury, which are reviewed in Table 1. Zhu et al were the
first to investigate LC3-II level following cerebral HI. They sub-
jected mice of different postnatal ages (from P5 to P60) to the
Rice-Vannucci model and concluded that there was a significant
increase in LC3-II at all ages even though it was  more pronounced
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Table  1
Autophagy in in vivo models of neonatal cerebral hypoxia-ischemia and human newborn autoptic studies. AIF: apoptosis inducing factor; CathB/CathD: cathepsin B/D;
r/l/t  CCAO: right/left/transient common carotid artery occlusion; O2: oxygen, EM:  electron microscopy (presence of autophagosomes and autolysosomes); ER; endoplasmic
reticulum; GA: gestational age; hipp: hippocampus; HI: hypoxia-ischemia; HIE: hypoxic-ischemic encephalopathy; IC: internal capsule; icv: intra-cerebro-ventricular; ip:
intra-peritoneal; MCAO: middle cerebral artery occlusion; MDC: monodansylcadaverine; nd: not determined; ROIs: regions of interest; SD: Sprague Dawley; striat: striatum;
thal:  thalamus; WMI:  white matter injury; WT:  wortmannin, shRNA: small or short hairpin RNA.
Model Age ROIs Autophagy
markers
Auto-phagicflux Relationship with
other cell death
Neuroprotective
strategies targeting
autophagy
References
MOUSE
l CCAO, 40–60 min  10%
O2
P5, 9,21, 60 Cortex, hipp, thal.,
striat.
LC3 ↗ nd. nd. nd. (Zhu et al., 2005)
RAT SD
r CCAO, 90 min  8% O2
P7 Cortex LC3, Beclin1 ↗,  EM nd. nd. nd. (Shi et al., 2012)
RAT SD
r CCAO 90 min  8% O2
P7 Cortex, hipp LC3, Beclin1,
lyso-trackers ↗
nd. nd. nd. (Weis et al., 2014)
RAT SD
r CCAO, 2 h 8% O2
P7 Thal. (ventrolat.
nucleus)
LC3, LAMP1, CathD,
lysosomal activity
↗,  p62 ↘
↗ colocalization caspase
3 and LAMP-1.
EM:  mixed features
autophagy and
apoptosis
nd. (Ginet et al., 2014a)
RAT SD
r CCAO, 2 h 8% O2
P7 Cortex, hipp LC3, LAMP1, CathD,
lysosomal activity
↗,  EM
↗ colocalization caspase
3 and LAMP-1.
EM:  mixed features
autophagy and
apoptosis in the cortex
nd. (Ginet et al., 2009)
RAT SD
r CCAO, 2 h 8% O2
P7 Thal LC3 ↗ nd. nd. nd. (Ginet et al., 2009)
Neuroprotection by autophagy inhibition
MOUSE
l CCAO, 40 min  8% O2
P7 Hipp. LC3 ↗ and EM nd. EM:  mixed features
autophagy and
apoptosis.
Atg7 deficient mice: ↘
lesion volume
(Koike et al., 2008)
RAT SD
r CCAO, 2 h 8% O2
P7 Striat LC3, LAMP1, CathB,
lysosomal activity
↗ p62 ↘
↗ nd. Intrastriatal injections
of lentiviral vectors
transducing Beclin-1
shRNA: ↘ lesion
volume
(Ginet et al., 2014b)
RAT SD
l MCAO + 90 min
t  CCAO
P12 Cortex LC3, LAMP1,
lysosomal activity
↗
EM
↗ 3-MA ↘ cleaved
caspase-3 and -9 and
AIF nuclear
translocation.
3-MA icv after MCAO:
↘ lesion volume
(Puyal et al., 2009)
RAT SD
r CCAO, 2 h 8% O2
P7 Hipp. (CA3) LC3, LAMP1 ↗ nd. nd. Neriifolin ip before HI:
↘ lesion volume.
(Liu et al., 2013)
RAT Wistar
r CCAO, 50 min  7.7% O2
P9 Cortex, hipp, thal,
striat
LC3 ↗ nd. nd. Lithium chloride ip
after HI: ↘ lesion
volume
(Li et al., 2000)
Neuroprotection by autophagy induction
RAT SD
r CCAO, 2,5 h 8% O2
P7 Cortex, hipp Beclin1 ↗ nd. Colocalization of
Beclin-1 and TUNEL
staining.
Rapamycin and 3-MA
↘ cleaved caspase-3.
Rapamycin icv 20 min
before HI: ↘ lesion
volume.
3-MA or WT  icv 20 min
before HI: no ↘ lesion
volume.
(Carloni et al., 2008)
RAT SD
r CCAO, 2.5 h 8% O2
P7 Cortex, hipp LC3, Beclin1, MDC
↗
↗ nd. Rapamycin icv 30min
before HI: ↘ lesion
volume
(Carloni et al., 2010)
RAT SD
r CCAO, 2,5 h 8% O2
P7 Cortex, hipp LC3, Beclin1, MDC
↗
↗ Rapamycin ↘ ER stress
and unfolded protein
response.
Rapamycin icv 30min
before HI: ↘ lesion
volume
3-MA 20min before HI:
no ↘ lesion volume.
(Carloni et al., 2014)
Human autoptic studies
Premature HUMAN
(WMI)
<32 GA Thal and IC LC3, LAMP1 ↗ nd. nd. nd. (Vontell et al., 2015)
Newborn HUMAN
(HIE)
35–42 GA Thal (ventrolat n) LC3, LAMP1, p62,
CathD ↗
↗ Colocalization caspase
3/LAMP-1 and
CathD/TUNEL staining.
nd. (Ginet et al., 2009)
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in adult brains. Later, in both rat and mouse models of perinatal
HI, ultrastructural studies revealed numerous autophagosomes and
autolysosomes in the cytosol of dying neurons (Ginet et al., 2009;
Koike et al., 2008; Zhu et al., 2005). In P7 hypoxic-ischemic rat pups,
our group showed that an LC3-II increase was already detectable
as soon as 6 h after the insult and peaked at around 24 h (Ginet
et al., 2014a; Ginet et al., 2009). Autophagic flux enhancement was
suggested by an increase in both LC3-positive dots and lysosomal
markers (LAMP1, cathepsins) and activity (acid phosphatase, "-
hexosaminidase) that can occur in the same dying neurons (Ginet
et al., 2009). A decrease in p62/SQSTM1 was also observed (Ginet
et al., 2014a; Ginet et al., 2014b). Depending on the cerebral region,
the pattern of HI-induced autophagy can vary (Ginet et al., 2009;
Weis et al., 2014) with for instance an earlier activation in the
rat cortex and hippocampal CA3 than in the thalamus or striatum
(Ginet et al., 2009).
Few studies have addressed the functional role of enhanced
autophagy in neonatal cerebral HI models until now. All the stud-
ies suggest that enhanced autophagy plays a role in the apoptotic
pathway since dying neurons can express both autophagic and
apoptotic features (Carloni et al., 2008; Ginet et al., 2014a; Ginet
et al., 2009; Koike et al., 2008) and since autophagy inhibition
decreases apoptotic markers such as caspase-3 activation (Carloni
et al., 2008; Koike et al., 2008). Interestingly, we showed that
autophagy could mediate apoptosis in primary cortical neurons
cultures treated with classical apoptotic stimuli (Grishchuk et al.,
2011). However this interaction between autophagy and apoptosis
may  depend on the cerebral region. In the rat cortex our results indi-
cate that enhanced autophagy is related to apoptosis since some
highly autophagic neurons expressed also cleaved caspase-3 and
most of the dying cortical neurons presented a mixture of apoptotic
(chromatin condensation, cytoplasmic shrinkage) and autophagic
(autophagosomes, autolysosomes) morphological characteristics
by electron microscopy. However, in the hippocampus, there was
a region-specific dichotomy in cell death type: CA3 neurons dis-
played a strong increase in autophagy without apoptosis (probably
a type of autophagic cell death), whereas CA1 neurons were highly
apoptotic but not autophagic (Ginet et al., 2009).
Most of the studies investigating the role of autophagy in neona-
tal cerebral HI employed pharmacological inhibitors of limited
specificity, so prudence is required concerning the conclusions
(Hughes and Kennedy Cell biology, 2012; Wu et al., 2010). In a rat
cerebral HI model the studies of Carloni and collaborators reported
a beneficial effect of autophagy stimulation with rapamycin on
apoptotic cell death, endoplasmic reticulum stress and brain dam-
age (Carloni et al., 2014; Carloni et al., 2008; Carloni et al., 2010).
Since rapamycin was administrated in pre-treatment, the possible
benefit of a sort of pre-conditioning could not be excluded (Sheng
and Qin, 2015). Autophagy inhibition with 3-MA in the same model
showed no significant difference in the size of the brain lesion vol-
ume  (Carloni et al., 2008). However the dose of 3-MA used in this
study was weaker than those necessary to provide neuroprotec-
tion in other studies (Puyal et al., 2009; Wen  et al., 2008). 3-MA
was also injected before HI whereas post-treatment with 3-MA in a
rat model of neonatal stroke showed strong neuroprotective effect
(Puyal et al., 2009). Intraperitoneal injection of the cardiac glycoside
neriifolin, a highly potent Na+/K+ ATPase inhibitor that has been
shown to prevent autosis (a type of autophagic cell death), atten-
uated the autophagosome increase and drastically reduced brain
damage one week after perinatal cerebral HI (Liu et al., 2013).
However, to date, the stronger evidence for a death-promoting
role of enhanced autophagy after perinatal HI comes from studies
using genetic methodologies to inhibit autophagy such as neuron-
specific knockout (KO) of Atg7 (Koike et al., 2008) or knockdown of
Beclin1 (Ginet et al., 2014b). Thus, the hippocampus was  resistant
to HI (compared to WT)  in KO mice deficient for Atg7 specifically in
neurons (Koike et al., 2008) and knockdown of Beclin-1 by intrastri-
atal injection of lentiviral vectors transducing shRNA was  likewise
neuroprotective against HI (Ginet et al., 2014b).
More in vivo studies investigating the autophagic flux and
specifically manipulating the autophagic pathway at a genetic level
are still needed to provide solid data on the role of autophagy in
neonatal HI.
5.3. Autophagy in human neonates with cerebral HI
Human studies investigating the molecular pathophysiological
mechanisms of perinatal brain injuries are still too sparse to clearly
identify the time course and clinical implication. However, it is
known that classical apoptosis is rarely seen in the human neonatal
brain after HIE, highlighting the importance of better understand-
ing the crosstalk between the different cellular death pathways
(Northington et al., 2011).
Only two  studies have investigated autophagy in autopsied
brains of human neonates presenting cerebral lesions. In a recent
study focused mainly on the toll-like receptor 3, (Vontell et al.,
2015) examined LC3 immunolabelling in post-mortem brain sec-
tions of autopsied preterm newborns (<32 weeks of gestational
age) with diagnosed white matter injury. They showed an increase
in LC3-positive dots (autophagosomes) in the injured thalamus.
The LC3 dots colocalized with a mitochondrial marker suggest-
ing increased mitophagy. However their main inclusion criterion
was the presence of white matter injury and they thus did not
specifically address HIE.
Our group recently showed for the first time that autophagy
was enhanced in the brains of human term newborns (35–7 weeks
gestational age) who  died from perinatal asphyxia and severe HIE
(Ginet et al., 2014a). We  analyzed the ventrolateral nucleus of
the thalamus since this cerebral region is known to be highly
sensitive to cerebral asphyxia. We  showed an increase in both
autophagosomal (punctate LC3) and lysosomal (LAMP1, Cathepsin
D) markers occurring in dying neurons of HIE human newborns.
Moreover, p62/SQSTM1 labelling was strongly decreased argu-
ing for an increase in the autophagic flux. We also showed that
autophagic and apoptotic markers were expressed in the same
dying neurons. Altogether these data indicate that autophagy is
increased in the brains of hypoxic-ischemic newborns and associ-
ated with neuronal death.
5.4. Summary
To summarize, until now 15 studies have investigated the role of
autophagy in in vivo rodent models of neonatal cerebral HI, but only
half of them examined its neuroprotective potential by inhibition
or enhancement of autophagy. The majority of the studies favors
the concept of a death-promoting effect of autophagy-mediated
cell death in neonatal HIE.
6. Conclusion
The existence of multiple types of cell death, and of different
death-mediating pathways even in a single neuron, may  explain
the difficulty up until now of developing effective techniques of
neuroprotection, because attempts at neuroprotection have often
relied on targeting just a single pathway. But current understanding
of the different death pathways, and of the crosstalk between them,
is still limited and much more research is needed. In particular, the
relatively new concept of autophagy-mediated cell death deserves
considerable attention in the coming years.
C. Descloux et al. / Int. J. Devl Neuroscience 45 (2015) 75–85 83
Acknowledgements
Our research on autophagy was supported by grants from the
Swiss National Science Foundation(310030-130769), the Emma
Muschamp Foundation and the Faculty of Biology and Medicine of
the University of Lausanne. The salary of CD is supported by the Spe-
cial Program of University Medicine of the Swiss National Research
Foundation (33CM30-124101). We  thank the Electron Microscopy
Facility (University of Lausanne) for technical and experimental
support.
References
Adachi, M.,  Sohma, O., Tsuneishi, S., Takada, S., Nakamura, H., 2001. Combination
effect of systemic hypothermia and caspase inhibitor administration against
hypoxic-ischemic brain damage in neonatal rats. Pediatr Res 50, 590–595.
Adhami, F., Liao, G., Morozov, Y.M., Schloemer, A., Schmithorst, V.J., Lorenz, J.N.,
Dunn, R.S., Vorhees, C.V., Wills-Karp, M.,  Degen, J.L., Davis, R.J., Mizushima, N.,
Rakic, P., Dardzinski, B.J., Holland, S.K., Sharp, F.R., Kuan, C.Y., 2006. Cerebral
ischemia-hypoxia induces intravascular coagulation and autophagy. Am J
Pathol 169, 566–583.
Akpan, N., Troy, C.M., 2013. Caspase inhibitors: prospective therapies for stroke.
Neuroscientist 19, 129–136.
Arthur, P.G., Matich, G.P., Pang, W.W.,  Yu, D.Y., Bogoyevitch, M.A., 2007. Necrotic
death of neurons following an excitotoxic insult is prevented by a peptide
inhibitor of c-jun N-terminal kinase. J Neurochem 102, 65–76.
Azzopardi, D., Strohm, B., Marlow, N., Brocklehurst, P., Deierl, A., Eddama, O.,
Goodwin, J., Halliday, H.L., Juszczak, E., Kapellou, O., Levene, M.,  Linsell, L.,
Omar, O., Thoresen, M.,  Tusor, N., Whitelaw, A., Edwards, A.D., Group, T.S.,
2014. Effects of hypothermia for perinatal asphyxia on childhood outcomes. N
Engl J Med 371, 140–149.
Baburamani, A.A., Ek, C.J., Walker, D.W., Castillo-Melendez, M., 2012. Vulnerability
of  the developing brain to hypoxic-ischemic damage: contribution of the
cerebral vasculature to injury and repair? Front Physiol 3, 424.
Boland, B., Nixon, R.A., 2006. Neuronal macroautophagy: from development to
degeneration. Mol  Aspects Med  27, 503–519.
Borsello, T., Croquelois, K., Hornung, J.P., Clarke, P.G., 2003.
N-methyl–aspartate-triggered neuronal death in organotypic hippocampal
cultures is endocytic, autophagic and mediated by the c-Jun N-terminal kinase
pathway. Eur J Neurosci 18, 473–485.
Broughton, B.R., Reutens, D.C., Sobey, C.G., 2009. Apoptotic mechanisms after
cerebral ischemia. Stroke 40, e331–e339.
Carloni, S., Carnevali, A., Cimino, M.,  Balduini, W.,  2007. Extended role of necrotic
cell death after hypoxia-ischemia-induced neurodegeneration in the neonatal
rat.  Neurobiol Dis 27, 354–361.
Carloni, S., Buonocore, G., Balduini, W.,  2008. Protective role of autophagy in
neonatal hypoxia-ischemia induced brain injury. Neurobiol Dis 32, 329–339.
Carloni, S., Girelli, S., Scopa, C., Buonocore, G., Longini, M.,  Balduini, W.,  2010.
Activation of autophagy and Akt/CREB signaling play an equivalent role in the
neuroprotective effect of rapamycin in neonatal hypoxia-ischemia. autophagy
6,  366–377.
Carloni, S., Albertini, M.C., Galluzzi, L., Buonocore, G., Proietti, F., Balduini, W.,  2014.
Increased autophagy reduces endoplasmic reticulum stress after neonatal
hypoxia-ischemia: role of protein synthesis and autophagic pathways. Exp
Neurol 255, 103–112.
Carlsson, Y., Schwendimann, L., Vontell, R., Rousset, C.I., Wang, X., Lebon, S.,
Charriaut-Marlangue, C., Supramaniam, V., Hagberg, H., Gressens, P., Jacotot, E.,
2011. Genetic inhibition of caspase-2 reduces hypoxic-ischemic and
excitotoxic neonatal brain injury. Ann Neurol 70, 781–789.
Castillo, K., Valenzuela, V., Matus, S., Nassif, M.,  Onate, M.,  Fuentealba, Y., Encina,
G., Irrazabal, T., Parsons, G., Court, F.A., Schneider, B.L., Armentano, D., Hetz, C.,
2013. Measurement of autophagy flux in the nervous system in vivo. Cell
Death Dis 4, e917.
Chang, C.F., Huang, H.J., Lee, H.C., Hung, K.C., Wu,  R.T., Lin, A.M., 2012. Melatonin
attenuates kainic acid-induced neurotoxicity in mouse hippocampus via
inhibition of autophagy and alpha-synuclein aggregation. J Pineal Res 52,
312–321.
Chauvier, D., Renolleau, S., Holifanjaniaina, S., Ankri, S., Bezault, M.,
Schwendimann, L., Rousset, C., Casimir, R., Hoebeke, J., Smirnova, M., Debret,
G.,  Trichet, A.P., Carlsson, Y., Wang, X., Bernard, E., Hebert, M., Rauzier, J.M.,
Matecki, S., Lacampagne, A., Rustin, P., Mariani, J., Hagberg, H., Gressens, P.,
Charriaut-Marlangue, C., Jacotot, E., 2011. Targeting neonatal ischemic brain
injury with a pentapeptide-based irreversible caspase inhibitor. Cell Death Dis
2,  e203.
Chen, Y., Azad, M.B., Gibson, S.B., 2009. Superoxide is the major reactive oxygen
species regulating autophagy. Cell Death Differ 16, 1040–1052.
Clarke, P.G., Puyal, J., 2012. Autophagic cell death exists. Autophagy 8, 867–869.
Clarke, P.G.H., 1990. Developmental cell death: morphological diversity and
multiple mechanisms. Anat Embryol (Berl) 181, 195–213.
Cui, D., Wang, L., Qi, A., Zhou, Q., Zhang, X., Jiang, W.,  2012. Propofol prevents
autophagic cell death following oxygen and glucose deprivation in PC12 cells
and cerebral ischemia-reperfusion injury in rats. PLoS One 7, e35324.
Degterev, A., Huang, Z., Boyce, M.,  Li, Y., Jagtap, P., Mizushima, N., Cuny, G.D.,
Mitchison, T.J., Moskowitz, M.A., Yuan, J., 2005. Chemical inhibitor of
nonapoptotic cell death with therapeutic potential for ischemic brain injury.
Nat  Chem Biol 1, 112–119.
Delgado, M.E., Dyck, L., Laussmann, M.A., Rehm, M., 2014. Modulation of apoptosis
sensitivity through the interplay with autophagic and proteasomal
degradation pathways. Cell Death Dis 5, e1011.
Dong, X.X., Wang, Y.R., Qin, S., Liang, Z.Q., Liu, B.H., Qin, Z.H., Wang, Y., 2012. p53
mediates autophagy activation and mitochondria dysfunction in kainic
acid-induced excitotoxicity in primary striatal neurons. Neuroscience 207,
52–64.
Edinger, A.L., Thompson, C.B., 2004. Death by design: apoptosis, necrosis and
autophagy. Curr Opin Cell Biol 16, 663–669.
Edwards, A.D., Brocklehurst, P., Gunn, A.J., Halliday, H., Juszczak, E., Levene, M.,
Strohm, B., Thoresen, M.,  Whitelaw, A., Azzopardi, D., 2010. Neurological
outcomes at 18 months of age after moderate hypothermia for perinatal
hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data.
BMJ  340, c363.
Fan, T.-J., Han, L.-H., Cong, R.-S., Liang, J., 2005. Caspase Family Proteases and
Apoptosis. Acta Biochim Biophys. Sin. 37, 719–727.
Feng, Y., Fratkin, J.D., LeBlanc, M.H., 2003. Inhibiting caspase-8 after injury reduces
hypoxic–ischemic brain injury in the newborn rat. Eur J Pharmacol 481,
169–173.
Feng, Y., He, D., Yao, Z., Klionsky, D.J., 2014. The machinery of macroautophagy. Cell
Res  24, 24–41.
Ferriero, D.M., 2001. Oxidant mechanisms in neonatal hypoxia-ischemia. Dev
Neurosci 23, 198–202.
Ferriero, D.M., 2004. Neonatal brain injury. N Engl J Med 351, 1985–1995.
Fleiss, B., Tann, C.J., Degos, V., Sigaut, S., Van Steenwinckel, J., Schang, A.L., Kichev,
A.,  Robertson, N.J., Mallard, C., Hagberg, H., Gressens, P., 2015.
Inflammation-induced sensitization of the brain in term infants. Dev  Med
Child Neurol 57 (Suppl. 3), 17–28.
Fujita, N., Itoh, T., Omori, H., Fukuda, M.,  Noda, T., Yoshimori, T., 2008. The Atg16L
complex specifies the site of LC3 lipidation for membrane biogenesis in
autophagy. Mol  Biol Cell 19, 2092–2100.
Galluzzi, L., Maiuri, M.C., Vitale, I., Zischka, H., Castedo, M.,  Zitvogel, L., Kroemer, G.,
2007. Cell death modalities: classification and pathophysiological implications.
Cell Death Differ 14, 1237–1243.
Galluzzi, L., Kepp, O., Krautwald, S., Kroemer, G., Linkermann, A., 2014. Molecular
mechanisms of regulated necrosis. Semin Cell Dev Biol 35, 24–32.
Gao, W.,  Ding, W.X., Stolz, D.B., Yin, X.M., 2008. Induction of macroautophagy by
exogenously introduced calcium. Autophagy 4, 754–761.
Geng, J., Klionsky, D.J., 2008. The Atg8 and Atg12 ubiquitin-like conjugation
systems in macroautophagy. ‘Protein modifications: beyond the usual
suspects’ review series. EMBO Rep 9, 859–864.
Gill, R., Soriano, M., Blomgren, K., Hagberg, H., Wybrecht, R., Miss, M.T., Hoefer, S.,
Adam, G., Niederhauser, O., Kemp, J.A., Loetscher, H., 2002. Role of caspase-3
activation in cerebral ischemia-induced neurodegeneration in adult and
neonatal brain. J Cereb Blood Flow Metab 22, 420–430.
Ginet, V., Puyal, J., Clarke, P.G., Truttmann, A.C., 2009. Enhancement of autophagic
flux after neonatal cerebral hypoxia-ischemia and its region-specific
relationship to apoptotic mechanisms. Am J Pathol 175, 1962–1974.
Ginet, V., Pittet, M.P., Rummel, C., Osterheld, M.C., Meuli, R., Clarke, P.G., Puyal, J.,
Truttmann, A.C., 2014a. Dying neurons in thalamus of asphyxiated term
newborns and rats are autophagic. Ann Neurol 76, 695–711.
Ginet, V., Spiehlmann, A., Rummel, C., Rudinskiy, N., Grishchuk, Y., Luthi-Carter, R.,
Clarke, P.G., Truttmann, A.C., Puyal b, J., 2014b. Involvement of autophagy in
hypoxic-excitotoxic neuronal death. Autophagy 10, 846–860.
Gluckman, P.D., Wyatt, J.S., Azzopardi, D., Ballard, R., Edwards, A.D., Ferriero, D.M.,
Polin, R.A., Robertson, C.M., Thoresen, M.,  Whitelaw, A., Gunn, A.J., 2005.
Selective head cooling with mild systemic hypothermia after neonatal
encephalopathy: multicentre randomised trial. The Lancet 365, 663–670.
Grishchuk, Y., Ginet, V., Truttmann, A.C., Clarke, P.G., Puyal, J., 2011. Beclin
1-independent autophagy contributes to apoptosis in cortical neurons.
autophagy 7, 1115–1131.
Gunn, A.J., 2000. Cerebral hypothermia for prevention of brain injury following
perinatal asphyxia. Curr Opin Pediatr 12, 111–115.
Gurd, J.W., Bissoon, N., Beesley, P.W., Nakazawa, T., Yamamoto, T., Vannucci, S.J.,
2002. Differential effects of hypoxia-ischemia on subunit expression and
tyrosine phosphorylation of the NMDA receptor in 7- and 21-day-old rats. J
Neurochem 82, 848–856.
Hagberg, H., Mallard, C., Ferriero, D.M., Vannucci, S.J., Levison, S.W., Vexler, Z.S.,
Gressens, P., 2015. The role of inflammation in perinatal brain injury. Nat Rev
Neurol.
Haynes, R.L., Baud, O., Li, J., Kinney, H.C., Volpe, J.J., Folkerth, D.R., 2005. Oxidative
and nitrative injury in periventricular leukomalacia: a review. Brain Pathol 15,
225–233.
He, C., Klionsky, D.J., 2009. Regulation mechanisms and signaling pathways of
autophagy. Annu Rev Genet 43, 67–93.
Herlenius, E., Lagercrantz, H., 2001. Neurotransmitters and neuromodulators
during early human development. Early Hum Dev 65, 21–37.
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.,
Natsume, T., Takehana, K., Yamada, N., Guan, J.L., Oshiro, N., Mizushima, N.,
2009. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200
complex required for autophagy. Mol  Biol Cell 20, 1981–1991.
84 C. Descloux et al. / Int. J. Devl Neuroscience 45 (2015) 75–85
Hoyer-Hansen, M., Bastholm, L., Szyniarowski, P., Campanella, M., Szabadkai, G.,
Farkas, T., Bianchi, K., Fehrenbacher, N., Elling, F., Rizzuto, R., Mathiasen, I.S.,
Jaattela, M.,  2007. Control of macroautophagy by calcium,
calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol  Cell 25, 193–205.
Hughes, K.J., Kennedy Cell biology, B.K., 2012. Rapamycin paradox resolved.
Science 335, 1578–1579.
Itakura, E., Kishi, C., Inoue, K., Mizushima, N., 2008. Beclin 1 forms two distinct
phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG.
Mol  Biol Cell 19, 5360–5372.
Johansen, T., Lamark, T., 2011. Selective autophagy mediated by autophagic
adapter proteins. Autophagy 7, 279–296.
Johnston, M.V., Ferriero, D.M., Vannucci, S.J., Hagberg, H., 2005. Models of Cerebral
Palsy: Which Ones Are Best. J. Child Neurol. 20, 984–987.
Joly, L.M., Mucignat, V., Mariani, J., Plotkine, M.,  Charriaut-Marlangue, C., 2004.
Caspase inhibition after neonatal ischemia in the rat brain. J Cereb Blood Flow
Metab 24, 124–131.
Kawamura, M.,  Nakajima, W.,  Ishida, A., Ohmura, A., Miura, S., Takada, G., 2005.
Calpain inhibitor MDL  28,170 protects hypoxic-ischemic brain injury in
neonatal rats by inhibition of both apoptosis and necrosis. Brain Res 1037,
59–69.
Kim, H., Choi, J., Ryu, J., Park, S.G., Cho, S., Park, B.C., Lee do, H., 2009. Activation of
autophagy during glutamate-induced HT22 cell death. Biochem Biophys Res
Commun 388, 339–344.
Klionsky, D.J.e.a., 2012. Guidelines for the use and interpretation of assays for
monitoring autophagy. Autophagy 8, 445–544.
Koike, M.,  Shibata, M.,  Tadakoshi, M.,  Gotoh, K., Komatsu, M.,  Waguri, S., Kawahara,
N., Kuida, K., Nagata, S., Kominami, E., Tanaka, K., Uchiyama, Y., 2008.
Inhibition of autophagy prevents hippocampal pyramidal neuron death after
hypoxic-ischemic injury. Am J Pathol 172, 454–469.
Komatsu, M.,  Waguri, S., Chiba, T., Murata, S., Iwata, J., Tanida, I., Ueno, T., Koike, M.,
Uchiyama, Y., Kominami, E., Tanaka, K., 2006. Loss of autophagy in the central
nervous system causes neurodegeneration in mice. Nature 441,
880–884.
Kroemer, G., Levine, B., 2008. Autophagic cell death: the story of a misnomer. Nat
Rev Mol  Cell Biol 9, 1004–1010.
Kubota, C., Torii, S., Hou, N., Saito, N., Yoshimoto, Y., Imai, H., Takeuchi, T., 2010.
Constitutive reactive oxygen species generation from
autophagosome/lysosome in neuronal oxidative toxicity. J Biol Chem 285,
667–674.
Kulbe, J.R., Mulcahy Levy, J.M., Coultrap, S.J., Thorburn, A., Bayer, K.U., 2014.
Excitotoxic glutamate insults block autophagic flux in hippocampal neurons.
Brain Res 1542, 12–19.
Lau, A., Tymianski, M.,  2010. Glutamate receptors, neurotoxicity and
neurodegeneration. Pflugers Arch 460, 525–542.
Lee, I.H., Kawai, Y., Fergusson, M.M.,  Rovira, I.I., Bishop, A.J., Motoyama, N., Cao, L.,
Finkel, T., 2012. Atg7 modulates p53 activity to regulate cell cycle and survival
during metabolic stress. Science 336, 225–228.
Levine, B., Klionsky, D.J., 2004. Development by self-digestion molecular
mechanisms and biological functions of autophagy. Dev Cell 6, 463–477.
Li, H., Colbourne, F., Sun, P., Zhao, Z., Buchan, A.M., Iadecola, C., 2000. Caspase
inhibitors reduce neuronal injury after focal but not global cerebral ischemia in
rats.  Stroke 31, 176–182.
Linkermann, A., Green, D.R., 2014. Necroptosis. N Engl J Med  370, 455–465.
Liu, Y., Levine, B., 2015. Autosis and autophagic cell death: the dark side of
autophagy. Cell Death Differ 22, 367–376.
Liu, Y., Shoji-Kawata, S., Sumpter, R.M. Jr., Wei, Y., Ginet, V., Zhang, L., Posner, B.,
Tran, K.A., Green, D.R., Xavier, R.J., Shaw, S.Y., Clarke, P.G., Puyal, J., Levine, B.,
2013. Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by
autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl
Acad Sci U S A 110, 20364–20371.
Lockshin, R.A., Zakeri, Z., 2004. Apoptosis, autophagy, and more. Int J Biochem Cell
Biol  36, 2405–2419.
Lorek, A., Takei, Y., Cady, E.B., Wyatt, J.S., Penrice, J., Edwards, A.D., Peebles, D.,
Wylezinska, M., Owen-Reece, H., Kirkbride, V., et al., 1994. Delayed (secondary)
cerebral energy failure after acute hypoxia-ischemia in the newborn piglet:
continuous 48-hour studies by phosphorus magnetic resonance spectroscopy.
Pediatr Res 36, 699–706.
Maiuri, M.C., Criollo, A., Tasdemir, E., Vicencio, J.M., Tajeddine, N., Hickman, J.A.,
Geneste, O., Kroemer, G., 2007a. BH3-only proteins and BH3 mimetics induce
autophagy by competitively disrupting the interaction between Beclin 1 and
Bcl-2/Bcl-X(L). Autophagy 3, 374–376.
Maiuri, M.C., Zalckvar, E., Kimchi, A., Kroemer b, G., 2007b. Self-eating and
self-killing: crosstalk etween autophagy and apoptosis. Nat Rev Mol Cell Biol 8,
741–752.
Marino, G., Niso-Santano, M.,  Baehrecke, E.H., Kroemer, G., 2014.
Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol  Cell
Biol  15, 81–94.
Markgraf, C.G., Velayo, N.L., Johnson, M.P., McCarty, D.R., Medhi, S., Koehl, J.R.,
Chmielewski, P.A., Linnik, M.D., 1998. Six-hour window of opportunity for
calpain inhibition in focal cerebral ischemia in rats. Stroke 29, 152–158.
Matyja, E., Taraszewska, A., Naganska, E., Rafalowska, J., 2005. Autophagic
degeneration of motor neurons in a model of slow glutamate excitotoxicity in
vitro. Ultrastruct Pathol 29, 331–339.
McDonald, J.W., Silverstein, F.S., Johnston, M.V., 1988. Neurotoxicity of
N-methyl–aspartate is markedly enhanced in developing rat central nervous
system. Brain Res 459, 200–203.
Mehrpour, M.,  Esclatine, A., Beau, I., Codogno, P., 2010. Overview of
macroautophagy regulation in mammalian cells. Cell Res 20, 748–762.
Mehta, S.L., Manhas, N., Raghubir, R., 2007. Molecular targets in cerebral ischemia
for developing novel therapeutics. Brain Res Rev 54, 34–66.
Meloni, B.P., Meade, A.J., Kitikomolsuk, D., Knuckey, N.W., 2011. Characterisation of
neuronal cell death in acute and delayed in vitro ischemia (oxygen-glucose
deprivation) models. J Neurosci Methods 195, 67–74.
Nakajima, W.,  Ishida, A., Lange, M.S., Gabrielson, K.L., Wilson, M.A., Martin, L.J.,
Blue, M.E., Johnston, M.V., 2000. Apoptosis has a prolonged role in the
neurodegeneration after hypoxic ischemia in the newborn rat. J Neurosci 20,
7994–8004.
Nakatogawa, H., Ichimura, Y., Ohsumi, Y., 2007. Atg8, a ubiquitin-like protein
required for autophagosome formation, mediates membrane tethering and
hemifusion. Cell 130, 165–178.
Nedelcu, J., Klein, M.A., Aguzzi, A., Boesiger, P., Martin, E., 1999. Biphasic edema
after hypoxic-ischemic brain injury in neonatal rats reflects early neuronal and
late glial damage. Pediatr Res 46, 297–304.
Neumar, R.W., Meng, F.H., Mills, A.M., Xu, Y.A., Zhang, C., Welsh, F.A., Siman, R.,
2001. Calpain activity in the rat brain after transient forebrain ischemia. Exp
Neurol 170, 27–35.
Nikoletopoulou, V., Markaki, M.,  Palikaras, K., Tavernarakis, N., 2013. Crosstalk
between apoptosis, necrosis and autophagy. Biochim Biophys Acta 1833,
3448–3459.
Niquet, J., Baldwin, R.A., Allen, S.G., Fujikawa, D.G., Wasterlain, C.G., 2003. Hypoxic
neuronal necrosis: protein synthesis-independent activation of a cell death
program. Proc Natl Acad Sci U S A 100, 2825–2830.
Nitatori, T., Sato, N., Waguri, S., Karasawa, Y., Araki, H., Shibanai, K., Kominami, E.,
Uchiyama, Y., 1995. Delayed neuronal death in the CA1 pyramidal cell layer of
the gerbil hippocampus following transient ischemia is apoptosis. J Neurosci
15, 1001–1011.
Northington, F.J., Ferriero, D.M., Graham, E.M., Traystman, R.J., Martin, L.J., 2001.
Early Neurodegeneration after Hypoxia-Ischemia in Neonatal Rat Is Necrosis
while Delayed Neuronal Death Is Apoptosis. Neurobiol Dis 8, 207–219.
Northington, F.J., Chavez-Valdez, R., Martin, L.J., 2011. Neuronal cell death in
neonatal hypoxia-ischemia. Ann Neurol 69, 743–758.
Olney, J.W., Ho, O.L., 1970. Brain damage in infant mice following oral intake of
glutamate, aspartate or cysteine. Nature 227, 609–611.
Perez-Carrion, M.D., Perez-Martinez, F.C., Merino, S., Sanchez-Verdu, P.,
Martinez-Hernandez, J., Lujan, R., Cena, V., 2012. Dendrimer-mediated siRNA
delivery knocks down Beclin 1 and potentiates NMDA-mediated toxicity in rat
cortical neurons. J Neurochem 120, 259–268.
Pun, P.B., Lu, J., Moochhala, S., 2009. Involvement of ROS in BBB dysfunction. Free
Radic Res 43, 348–364.
Puyal, J., Clarke, P.G., 2009. Targeting autophagy to prevent neonatal stroke
damage. Autophagy 5, 1060–1061.
Puyal, J., Vaslin, A., Mottier, V., Clarke, P.G., 2009. Postischemic treatment of
neonatal cerebral ischemia should target autophagy. Ann Neurol 66, 378–389.
Puyal, J., Ginet, V., Grishchuk, Y., Truttmann, A.C., Clarke, P.G., 2012. Neuronal
autophagy as a mediator of life and death: contrasting roles in chronic
neurodegenerative and acute neural disorders. Neuroscientist 18, 224–236.
Puyal, J., Ginet, V., Clarke, P.G., 2013. Multiple interacting cell death mechanisms in
the  mediation of excitotoxicity and ischemic brain damage: a challenge for
neuroprotection. Prog Neurobiol 105, 24–48.
Rami, A., Langhagen, A., Steiger, S., 2008. Focal cerebral ischemia induces
upregulation of Beclin 1 and autophagy-like cell death. Neurobiol Dis 29,
132–141.
Rennie, J.M., Hagmann, C., Robertson, N.J., 2008. The Baby Who  Was  Depressed at
Birth in Neonatal Cerebral Investigation. In: Cambridge University Press., pp.
130–138, Chapter 8.
Rice 3rd, J.E., Vannucci, R.C., Brierley, J.B., 1981. The influence of immaturity on
hypoxic-ischemic brain damage in the rat. Ann Neurol 9, 131–141.
Sadasivan, S., Zhang, Z., Larner, S.F., Liu, M.C., Zheng, W.,  Kobeissy, F.H., Hayes, R.L.,
Wang, K.K., 2010. Acute NMDA toxicity in cultured rat cerebellar granule
neurons is accompanied by autophagy induction and late onset autophagic cell
death phenotype. BMC  Neurosci 11, 21.
Sattler, R., Tymianski, M.,  2000. Molecular mechanisms of calcium-dependent
excitotoxicity. J Mol  Med  (Berl) 78, 3–13.
Scherz-Shouval, R., Shvets, E., Fass, E., Shorer, H., Gil, L., Elazar, Z., 2007. Reactive
oxygen species are essential for autophagy and specifically regulate the
activity of Atg4. EMBO J 26, 1749–1760.
Shacka, J.J., Lu, J., Xie, Z.L., Uchiyama, Y., Roth, K.A., Zhang, J., 2007. Kainic acid
induces early and transient autophagic stress in mouse hippocampus. Neurosci
Lett 414, 57–60.
Shang, L., Wang, X., 2011. AMPK and mTOR coordinate the regulation of Ulk1 and
mammalian autophagy initiation. autophagy 7, 924–926.
Shankaran, S., Laptook, A.R., Ehrenkranz, R.A., Tyson, J.E., McDonald, S.A., Donovan,
E.F., Fanaroff, A.A., Poole, W.K., Wright, L.L., Higgins, R.D., Finer, N.N., Carlo,
W.A., Duara, S., Oh, W.,  Cotten, C.M., Stevenson, D.K., Stoll, B.J., Lemons, J.A.,
Guillet, R., Jobe, A.H., National Institute of Child, H., Human Development
Neonatal Research, N., 2005. Whole-body hypothermia for neonates with
hypoxic-ischemic encephalopathy. N Engl J Med  353, 1574–1584.
Shankaran, S., Pappas, A., McDonald, S.A., Vohr, B.R., Hintz, S.R., Yolton, K.,
Gustafson, K.E., Leach, T.M., Green, C., Bara, R., Petrie Huitema, C.M.,
Ehrenkranz, R.A., Tyson, J.E., Das, A., Hammond, J., Peralta-Carcelen, M.,  Evans,
P.W., Heyne, R.J., Wilson-Costello, D.E., Vaucher, Y.E., Bauer, C.R., Dusick, A.M.,
Adams-Chapman, I., Goldstein, R.F., Guillet, R., Papile, L.A., Higgins, R.D., Eunice
C. Descloux et al. / Int. J. Devl Neuroscience 45 (2015) 75–85 85
Kennedy Shriver, N.N.R.N., 2012. Childhood outcomes after hypothermia for
neonatal encephalopathy. N Engl J Med  366, 2085–2092.
Sheng, R., Qin, Z.H., 2015. The divergent roles of autophagy in ischemia and
preconditioning. Acta Pharmacol Sin 36, 411–420.
Shi, R., Weng, J., Zhao, L., Li, X.M., Gao, T.M., Kong, J., 2012. Excessive autophagy
contributes to neuron death in cerebral ischemia. CNS Neurosci Ther 18,
250–260.
Simonsen, Tooze, 2009. Coordination of membrane events during autophagy by
multiple class III PI3-kinase complexes. J Cell Biol 186 (September (6)),
773–782.
Sou, Y.S., Waguri, S., Iwata, J., Ueno, T., Fujimura, T., Hara, T., Sawada, N., Yamada,
A.,  Mizushima, N., Uchiyama, Y., Kominami, E., Tanaka, K., Komatsu, M.,  2008.
The Atg8 conjugation system is indispensable for proper development of
autophagic isolation membranes in mice. Mol  Biol Cell 19, 4762–4775.
Takizawa, Y., Takashima, S., Itoh, M.,  2006. A histopathological study of premature
and mature infants with pontosubicular neuron necrosis: neuronal cell death
in  perinatal brain damage. Brain Res 1095, 200–206.
Talos, D.M., Fishman, R.E., Park, H., Folkerth, R.D., Follett, P.L., Volpe, J.J., Jensen, F.E.,
2006. Developmental regulation of
alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor
subunit expression in forebrain and relationship to regional susceptibility to
hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex. J Comp
Neurol 497, 42–60.
Taniguchi, H., Mohri, I., Okabe-Arahori, H., Kanekiyo, T., Kagitani-Shimono, K.,
Wada, K., Urade, Y., Nakayama, M.,  Ozono, K., Taniike, M.,  2007. Early induction
of  neuronal lipocalin-type prostaglandin D synthase after hypoxic-ischemic
injury in developing brains. Neurosci Lett 420, 39–44.
Tasdemir, E., Maiuri, M.C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M.,  D’Amelio,
M.,  Criollo, A., Morselli, E., Zhu, C., Harper, F., Nannmark, U., Samara, C., Pinton,
P.,  Vicencio, J.M., Carnuccio, R., Moll, U.M., Madeo, F., Paterlini-Brechot, P.,
Rizzuto, R., Szabadkai, G., Pierron, G., Blomgren, K., Tavernarakis, N., Codogno,
P.,  Cecconi, F., Kroemer, G., 2008. Regulation of autophagy by cytoplasmic p53.
Nat  Cell Biol 10, 676–687.
Thornton, C., Rousset, C.I., Kichev, A., Miyakuni, Y., Vontell, R., Baburamani, A.A.,
Fleiss, B., Gressens, P., Hagberg, H., 2012. Molecular mechanisms of neonatal
brain injury. Neurol Res Int 2012, 506320.
Tian, F., Deguchi, K., Yamashita, T., Ohta, Y., Morimoto, N., Shang, J., Zhang, X., Liu,
N.,  Ikeda, Y., Matsuura, T., Abe, K., 2010. In vivo imaging of autophagy in a
mouse stroke model. Autophagy 6, 1107–1114.
Uchiyama, Y., Shibata, M.,  Koike, M.,  Yoshimura, K., Sasaki, M., 2008.
Autophagy-physiology and pathophysiology. Histochem Cell Biol 129,
407–420.
Ullman, E., Fan, Y., Stawowczyk, M.,  Chen, H.M., Yue, Z., Zong, W.X., 2008.
Autophagy promotes necrosis in apoptosis-deficient cells in response to ER
stress. Cell Death Differ 15, 422–425.
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., Kroemer, G., 2010. Molecular
mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell
Biol 11, 700–714.
Vannucci, S.J., Hagberg, H., 2004. Hypoxia-ischemia in the immature brain. J Exp
Biol 207, 3149–3154.
Vontell, R., Supramaniam, V., Wyatt-Ashmead, J., Gressens, P., Rutherford, M.,
Hagberg, H., Thornton, C., 2015. Cellular mechanisms of toll-like receptor-3
activation in the thalamus are associated with white matter injury in the
developing brain. J Neuropathol Exp Neurol 74, 273–285.
Wang, Y., Gu, Z.L., Cao, Y., Liang, Z.Q., Han, R., Bennett, M.C., Qin, Z.H., 2006.
Lysosomal enzyme cathepsin B is involved in kainic acid-induced
excitotoxicity in rat striatum. Brain Res 1071, 245–249.
Wang, Y., Han, R., Liang, Z.Q., Wu,  J.C., Zhang, X.D., Gu, Z.L., Qin, Z.H., 2008. An
autophagic mechanism is involved in apoptotic death of rat striatal neurons
induced by the non-N-methyl–aspartate receptor agonist kainic acid.
Autophagy 4, 214–226.
Weis, S.N., Toniazzo, A.P., Ander, B.P., Zhan, X., Careaga, M.,  Ashwood, P., Wyse, A.T.,
Netto, C.A., Sharp, F.R., 2014. Autophagy in the brain of neonates following
hypoxia-ischemia shows sex- and region-specific effects. Neuroscience 256,
201–209.
Wen, Y.D., Sheng, R., Zhang, L.S., Han, R., Zhang, X., Zhang, X.D., Han, F., Fukunaga,
K.,  Qin, Z.H., 2008. Neuronal injury in rat model of permanent focal cerebral
ischemia is associated with activation of autophagic and lysosomal pathways.
Autophagy 4, 762–769.
Wu,  Y.T., Tan, H.L., Shui, G., Bauvy, C., Huang, Q., Wenk, M.R., Ong, C.N., Codogno, P.,
Shen, H.M., 2010. Dual role of 3-methyladenine in modulation of autophagy
via different temporal patterns of inhibition on class I and III phosphoinositide
3-kinase. J Biol Chem 285, 10850–10861.
Xing, S., Zhang, Y., Li, J., Zhang, J., Li, Y., Dang, C., Li, C., Fan, Y., Yu, J., Pei, Z., Zeng, J.,
2012. Beclin 1 knockdown inhibits autophagic activation and prevents the
secondary neurodegenerative damage in the ipsilateral thalamus following
focal cerebral infarction. Autophagy 8, 63–76.
Xiong, M.,  Li, J., Ma,  S.M., Yang, Y., Zhou, W.H., 2013. Effects of hypothermia on
oligodendrocyte precursor cell proliferation, differentiation and maturation
following hypoxia ischemia in vivo and in vitro. Exp Neurol 247,
720–729.
Xu, F., Li, J., Ni, W.,  Shen, Y.W., Zhang, X.P., 2013. Peroxisome proliferator-activated
receptor-gamma agonist 15d-prostaglandin J2 mediates neuronal autophagy
after cerebral ischemia-reperfusion injury. PLoS One 8, e55080.
Yager, J.Y., Ashwal, S., 2009. Animal models of perinatal hypoxic-ischemic brain
damage. Pediatr Neurol 40, 156–167.
Yamashima, T., Tonchev, A.B., Tsukada, T., Saido, T.C., Imajoh-Ohmi, S., Momoi, T.,
Kominami, E., 2003. Sustained calpain activation associated with lysosomal
rupture executes necrosis of the postischemic CA1 neurons in primates.
Hippocampus 13, 791–800.
Young, M.M.,  Takahashi, Y., Khan, O., Park, S., Hori, T., Yun, J., Sharma, A.K., Amin, S.,
Hu, C.D., Zhang, J., Kester, M.,  Wang, H.G., 2012. Autophagosomal membrane
serves as platform for intracellular death-inducing signaling complex
(iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem 287,
12455–12468.
Yuan, J., Kroemer, G., 2010. Alternative cell death mechanisms in development and
beyond. Genes Dev 24, 2592–2602.
Zhang, X., Yan, H., Yuan, Y., Gao, J., Shen, Z., Cheng, Y., Shen, Y., Wang, R.R., Wang,
X., Hu, W.W.,  Wang, G., Chen, Z., 2013. Cerebral ischemia-reperfusion-induced
autophagy protects against neuronal injury by mitochondrial clearance.
Autophagy 9, 1321–1333.
Zhu, C., Wang, X., Xu, F., Bahr, B.A., Shibata, M., Uchiyama, Y., Hagberg, H.,
Blomgren, K., 2005. The influence of age on apoptotic and other mechanisms of
cell death after cerebral hypoxia-ischemia. Cell Death Differ 12, 162–176.
“Enhanced autophagy contributes to excitotoxic lesions in a rat model
of preterm brain injury”
Descloux C, Ginet V, Rummel C, Truttmann AC, Puyal J in Cell Death and Disease, aug.
2018.
 
La leucomalacie périventriculaire est une lésion cérébrale soit diffuse, soit kystique, qui se
manifeste souvent chez des enfants prématurés ayant présenté une condition systémique
ischémique de type sepsis, entérocolite nécrosante ou asphyxie néonatale, résultant de lésions
hypoxiques-ischémiques sévères de la matière blanche cérébrale et impliquant également des
dommages au niveau de la matière grise. Les voies de signalisation menant aux différents
mécanismes de mort cellulaire dans ce type de lésion cérébrale chez le prématuré restent
encore très peu élucidées. L’excitotoxicité est un mécanisme prépondérant impliqué dans la
formation de lésions hypoxiques-ischémiques dans le cerveau en développement. Il a été
récemment démontré que l’autophagie pouvait être excessivement augmentée dans des
conditions d’excitotoxicité, transformant ce mécanisme physiologique de dégradation
intracellulaire en un processus délétère pour la cellule. Dans la présente étude, nous avons
investigué le rôle de l’autophagie dans un modèle reconnu de lésion excitotoxique périnatale
chez le rat, reproduisant les lésions de type « leucomalacie kystique périventriculaire »
retrouvée chez l’humain prématuré. Une lésion de type excitotoxique affectant les matières
grise et blanche a été induite par l’injection d’ibotenate, un analogue du glutamate, au niveau
de la matière blanche sous-corticale (aire sous-cingulaire) chez des ratons âgés de 5 jours.
L’injection d’ibotenate a causé une augmentation de l’autophagie dans les neurones en voie
de mort cellulaire après 6h, comme démontré par la présence augmentée d’autophagosomes
(augmentation de l’expression de LC3-II et du marquage ponctiforme LC3-positif) ainsi que
l’augmentation de la dégradation autophagique (diminution de l’expression de SQSTM1 et
augmentation du nombre et de la taille des lysosomes (vésicules positives pour LAMP1 et
CATHEPSIN-B)). La co-injection de 3-méthyladenine, inhibiteur pharmacologique de
l’autophagie, a montré une diminution non seulement de l’induction de l’autophagie, mais
également de l’activation de CASPASE-3 et du clivage calpaine- dépendant de SPECTRIN
24h après la lésion, induisant ainsi une diminution significative des lésions cérébrales à long
terme (16 jours après l’injection d’ibotenate). Notre étude a démontré une réduction
significative de la dilatation des ventricules latéraux, de la diminution du volume du tissu
cérébral ainsi que de la diminution de l’épaisseur de la matière blanche sous-corticale causées
par l’injection d’iboténate seul. L’effet neuroprotecteur « autophagie-dépendant » de la 3-
méthyladénine a également été confirmé dans des cultures primaires de neurones corticaux
par le moyen d’une inhibition pharmacologique mais également génétique de l’autophagie
excessive induite par le traitement à l’iboténate. Des stratégies basées sur l’inhibition de
l’autophagie pourraient donc représenter une approche neuroprotectrice prometteuse dans le
contexte des lésions cérébrales rencontrées chez les enfants prématurés.
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Enhanced autophagy contributes to
excitotoxic lesions in a rat model of
preterm brain injury
Céline Descloux1,2, Vanessa Ginet1, Coralie Rummel1, Anita C. Truttmann2 and Julien Puyal1
Abstract
Cystic periventricular leukomalacia is commonly diagnosed in premature infants, resulting from severe hypoxic-
ischemic white matter injury, and also involving some grey matter damage. Very few is known concerning the cell
death pathways involved in these types of premature cerebral lesions. Excitotoxicity is a predominant mechanism of
hypoxic-ischemic injury in the developing brain. Concomitantly, it has been recently shown that autophagy could be
enhanced in excitotoxic conditions switching this physiological intracellular degradation system to a deleterious
process. We here investigated the role of autophagy in a validated rodent model of preterm excitotoxic brain damage
mimicking in some aspects cystic periventricular leukomalacia. An excitotoxic lesion affecting periventricular white and
grey matter was induced by injecting ibotenate, a glutamate analogue, in the subcortical white matter (subcingulum
area) of ﬁve-day old rat pups. Ibotenate enhanced autophagy in rat brain dying neurons at 24 h as shown by increased
presence of autophagosomes (increased LC3-II and LC3-positive dots) and enhanced autophagic degradation
(SQSTM1 reduction and increased number and size of lysosomes (LAMP1- and CATHEPSIN B-positive vesicles)).
Co-injection of the pharmacological autophagy inhibitor 3-methyladenine prevented not only autophagy induction
but also CASPASE-3 activation and calpain-dependent cleavage of SPECTRIN 24 h after the insult, thus providing a
strong reduction of the long term brain injury (16 days after ibotenate injection) including lateral ventricle dilatation,
decreases in cerebral tissue volume and in subcortical white matter thickness. The autophagy-dependent
neuroprotective effect of 3-methyladenine was conﬁrmed in primary cortical neuronal cultures using not only
pharmacological but also genetic autophagy inhibition of the ibotenate-induced autophagy. Strategies inhibiting
autophagy could then represent a promising neuroprotective approach in the context of severe preterm brain injuries.
Introduction
The important progress done in neonatal care con-
stantly increases the survival rates of premature infants.
Conversely, the proportion of neurological disabilities
developed by survivors is hardly reduced especially for
those with severe impairment. One of them is the diplegic
cerebral palsy, called also spastic diplegia of Little1,
affecting still between 3–7% of very low birth weight
(VLBW) infants2,3. The strongest predictor of this
form of cerebral palsy in VLBW infants is cystic peri-
ventricular leukomalacia (cPVL)4, a form of preterm
white matter (WM) injury adjacent to the lateral ven-
tricles, which occurs either from a hypoxic-ischemic
(HI) event around birth or after infectious events such
as septic shock, necrotizing enterocolitis or even reported
after viral infections5,6. Improving the outcomes for
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these severely affected babies remains a challenging
health issue.
Beside inﬂammation and reactive oxygen species for-
mation, excitotoxicity seems to be crucial in the patho-
physiology of many preterm brain injuries such as
PVL3,7,8. Excitotoxicity consists in an excessive or pro-
longed activation of excitatory amino acid receptors
(especially those of glutamate) due to a failure of sufﬁcient
reuptake and/or excessive release at the synaptic level. It
induces a massive increase in intracellular calcium con-
centration and thus activates numerous intracellular
cascades potentially leading to neuronal cell death9,10.
Glutamate homeostasis is highly important for human
brain development (proliferation, migration, differentia-
tion, survival processes and synapses reﬁnement)11.
However it also confers to immature brain a vulnerability
to excitotoxic injuries since a higher level of ionotropic
glutamate receptors are expressed in developing brain
compared to that of adult8,12–15. These receptors are in
addition more readily activated. Excitotoxic lesions can
occur following a panel of deleterious events (that can be
related) such as infection/inﬂammation, hypoxia and/or
ischemia. Excitotoxicity is then a common pathological
mechanism of various perinatal brain injuries. In neurons
the peak of expression of NMDA receptors appears to
occur at term in which grey matter (GM) damage is
predominant than in preterm13. In human WM, this
peak occurs in preterm brain glial cells, especially in
pre-oligodendrocytes O4+, and contributes to the high
sensitivity of preterm WM. PVL was mainly thought
to be associated to WM injury but it is clearly shown now
that GM damage is also often involved in a “neuronal-
axonal disease”16,17.
Experimental research has revealed the complexity of
the pathophysiology of excitotoxic death showing multi-
ple and interrelating cell death mechanisms reﬂected by
mixed features of neuronal death including not only the
well-known “apoptotic-necrotic continuum” with features
of apoptosis and necrosis in the same dying neurons18 but
also characteristics of enhanced macroautophagy10,19–21.
Autophagy is a physiological cellular mechanism of
degradation and recycling of dysfunctioning long lived
proteins and organelles22. Its main form (macro-
autophagy, hereafter called autophagy), consists in the
formation of a multimembrane intermediate compart-
ment, named autophagosome, that engulfs part of the
cytosol containing proteins and organelles to be degraded.
The autophagosome then fuses with a lysosome, forming
an autolysosome, to degrade its content through lysoso-
mal hydrolases activity22. Autophagy is thus essential for
cellular homeostasis and could be used as a survival
response to different stresses such as nutrients depriva-
tion, accumulation of toxic proteins or pathogen inva-
sion23. However, dysregulated increase in autophagic
process has been also implicated in cell death as an
independent mechanism (termed “autophagic cell death”)
or more frequently as a mediator of other types of cell
death, mainly apoptosis, and then designed as “autophagy-
mediated cell death”10,24–28. Abnormal high level of
autophagosomes and autolysosomes with increased lyso-
somal enzyme activity were often observed in dying
neurons in models of excitotoxicity including perinatal
cerebral HI19,20,29–31. Interestingly, we also recently
demonstrated excessive autophagic features in post-
mortem brains of human term newborns presenting
severe hypoxic-ischemic encephalopathy (HIE)29,31.
Although controversies remain concerning the role of
autophagic activation24,32–35, most of the studies using
autophagy inhibition, either through pharmacological
inhibitors such as 3-methyladenine (3-MA)30,36–40 or
through speciﬁc and genetic inhibition of autophagy-
related genes (atg)20,29,31,41, have revealed a pro-death role
of autophagy in perinatal and adult cerebral HI models.
The present study aims to determine the role of
autophagy in excitotoxic lesions of the premature brain
using a widely recognized rodent model that mimics some
features of cPVL42. Autophagy ﬂux and the neuropro-
tective effect of autophagy inhibition either pharmacolo-
gically with 3-MA or genetically in neuronal cultures was
investigated in the context of an excitotoxic insult
induced by an injection of the glutamate analogue ibote-
nate. An involvement of autophagy in excitotoxic preterm
brain damage would reveal a new cellular death pathway
and open the way for new neuroprotective strategies in
severe preterm brain injuries.
Results
Ibotenate injection in subcortical WM of rat pups induces
brain injury
As a model mimicking some aspects of cPVL, we
selected a widely recognized model of preterm excitotoxic
brain injury consisting in applying an intracerebral
injection of ibotenate in rat pups42. The injection of ibo-
tenate (10 µg) in the subcortical WM at the level of the
right cingulum of 5-days-old rat pups causes a severe
brain damage of the WM and GM resulting in ventricular
enlargement as illustrated by cresyl-violet-stained coronal
sections in Fig. 1a 24 h and 16 days after the insult.
Immunoblot analysis of two death markers, the calpain-
dependent 150–145 kDa spectrin/fodrin (SPTAN) frag-
ment and cleaved CASPASE-3 (CASP3), indicated an
activation of both calcium-dependent necrotic cell death
and caspase-dependent apoptosis (Fig. 1b) at 6 and 24 h
after the insult (~5 and 14 fold increases respectively at
24 h). Although the proﬁle of CASP3 activation was
similar between females and males, we observed 24 h after
the insult a greater activation (~2 times more) in females.
Double immunolabeling showed that CASP3 was
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activated in neurons (RBFOX3-positive cells) 24 h after
ibotenate injection (Fig. 1c).
Ibotenate injection in subcortical WM of rat pups enhances
autophagic ﬂux in cortical neurons
To study the effect of intracerebral injection of ibote-
nate on autophagy, the expression levels of LC3-II
(the autophagosomal membrane bound form of LC3)
and Sequestosome-1 (SQSTM1, selectively degraded
by autophagy) in ipsilateral cortical extracts was ﬁrst
analyzed at 6 and 24 h after the ibotenate injection
(Fig. 2a). LC3-II was signiﬁcantly enhanced by ibotenate
compared to vehicle treated-rats (increase of 72% at 24 h)
whereas SQSTM1 was decreased (reduction of 23% at
24 h) suggesting an increase in the autophagy ﬂux in
females as well as in males. A quantiﬁcation of the
number of LC3-positive dots per neuron (RBFOX3-posi-
tive cells) conﬁrmed a signiﬁcant increase of 7.9 fold
in the number of autophagosomes in cortical neurons
24 h after the insult (Fig. 2b). Moreover, strong morpho-
logical features of enhanced autophagy could be observed
at the ultrastructural level (Fig. 2c). At earlier stage
(6 h after ibotenate injection), electron microscopy
revealed numerous multimembrane structures containing
undigested cellular contents (autophagosomes) and elec-
tron dense vacuoles containing cytoplasmic materials
Fig. 1 Ibotenate injection in subcortical white matter of rat pups induces brain injury. a Representative cresyl violet-stained coronal sections
illustrating the brain damage 24 h (at 6 postnatal days (P6)) and 16 days (P21) after ibotenate (Ibo) injection. Scale bar: 1 mm. b Ibo injection activates
both 150–145 kDa calpain-dependent cleavage of spectrin/fodrin (SPTAN) (veh: 100 ± 6.3%, 6 h Ibo: 284.4 ± 56.6%, 24 h Ibo: 528.1 ± 88.8%) and those
of caspase-3 (CASP3) (veh: 100 ± 7.13%, 6 h Ibo: 702.6 ± 210%, 24 h Ibo: 1430.9 ± 271.1%) as shown by representative immunoblots and the
corresponding quantiﬁcations. Mean CASP3 value is 870.7 ± 204.1% for males and 1929 ± 423.5% for females at 24 h. Mean SPTAN value is 312.1 ±
55.9% for males and 720.1 ± 132.5% for females at 24 h. (veh: n= 11 females, 10 males; 6 h: n= 7 females, 7 males; 24 h: n= 9 females, 8 males). Males
are represented by black triangles and females by white circles. c CASP3 is activated in neurons as revealed by double immunolabeling against
cleaved CASP3 (in red) and the neuronal marker RNA Binding Protein, Fox-1 Homolog 3 (RBFOX3)/NeuN (in green) 24 h after Ibo injection in neurons.
Scale bar: 20 µm. Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001
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at different stages of degradation (autolysomes) whereas
later on (at 24 h) hybrid phenotypes of cell death are
observed in dying neurons including apoptosis-like mor-
phological features (chromatin condensation), enhanced
autophagy (numerous autophagosomes and autolyso-
somes) and swollen organelles.
Finally, in addition to a higher number of autophago-
somes, autolysosomes were also more numerous in
neurons of ibotenate-treated rat pups than in vehicle-
treated animals. Immunohistochemistry and quantiﬁca-
tion of the number and the size of vesicles labeled with
antibodies against either a lysosomal membrane bound
protein, lysosomal-associated membrane protein 1
(LAMP1) (Fig. 3a), or a lysosomal enzyme (CATHEPSIN
B) (Fig. 3b) demonstrated an increase not only in
thenumber but also in the size of either LAMP1
(~4 fold) or CATHEPSIN B (~3 fold) positive-dots,
and especially those larger than 0.5 µm2 (increase of
29 and 23%, respectively) that are presumably autolyso-
somes. These results showed that ibotenate resulted in
enhancement of neuronal autophagy in the damaged
cortex of rat pups.
Fig. 2 Ibotenate injection in subcortical white matter of rat pups enhances autophagy in neurons. a Representative immunoblots and the
corresponding quantiﬁcations demonstrate an increase in LC3-II (veh: 100 ± 3.3%, 6 h Ibo: 125.6 ± 8.9%, 24 h Ibo: 173.2 ± 16.4%) and a decrease in
SQSTM1 (veh: 100 ± 1.7%, 6 h Ibo: 80.5 ± 2.4%, 24 h Ibo: 77.3 ± 4%) level of expression from 6 h after ibotenate (Ibo) injection. Mean LC3-II value
is 146.9 ± 12% for males and 196.6 ± 27.5% for females at 24 h. Mean SQSTM1 value is 81 ± 4.4% for males and 74 ± 6.5% for females at 24 h.
(veh: n= 11 females, 10 males; 6 h: n= 7 females, 7 males; 24 h: n= 9 females, 8 males). b Quantiﬁcation of LC3-positive dots (in red) per neuron
((RNA Binding Protein, Fox-1 Homolog 3) RBFOX3/NeuN (in green)) per µm2 on confocal images shows an increase in the number of
autophagosomes in the cortex 24 h after Ibo injection (veh: 0.0131 ± 0.001, Ibo: 0.1039 ± 0.0083). Mean LC3-positive dots per neuron per µm2 value is
0.1366 ± 0.0137% for males and 0.0711 ± 0.0079% for females treated with Ibo. Males are represented by black triangles and females by white circles.
Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001. Scale bars: 20 µm. c Ultrastructure analysis of damaged cortex reveals the presence of
numerous autophagosomes (multimembrane vacuoles, arrow heads) and autolysosomes (electron dense structures, arrows) in the cytosol at 6 and
24 h. Nuclear chromatin condensation and swollen organelles are observed at later stage (24 h). Nucleus (N). Scale bars: 1 µm
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Ibotenate induced-autophagy and -cell death are reduced
by pharmacological inhibition of autophagy
We then evaluated the role of this enhanced neuronal
autophagy on brain damage. Since long term autophagy
inhibition could be potentially deleterious particularly
for neurons43, we decided to manage the transient
inhibition of autophagy with the widely used pharmaco-
logical inhibitor of autophagy 3-MA. 3-MA was admi-
nistered in the ipsilateral ventricle just before ibotenate
injection as previously done in ischemic rat pups30.
As shown by immunoblots, ibotenate-induced increase
in LC3-II expression levels at 24 h was reduced by
Fig. 3 Ibotenate injection in subcortical white matter of rat pups increases autolysosomes formation in neurons. a Quantiﬁcation of LAMP1-
positive dots (in red) per neuron (MAP2 (in green)) per µm2 on confocal images shows an increase in the number of LAMP1-positive lysosomes in the
cortex 24 h after Ibo injection (number of dots: veh: 0.018 ± 0.002, Ibo: 0.075 ± 0.003/neurons/µm2). Mean value is 0.089 ± 0.005% for males and 0.057
± 0.004% for females treated with Ibo. On average, the measure of their size reveals the presence of larger LAMP1-positive dots following Ibo
injection (mean dot area: veh: 0.171 ± 0.002, Ibo: 0.685 ± 0.049 µm2) resulting from more dots larger than 0.5 µm2 (veh: 7.08 ± 1.90%, Ibo: 35.56 ±
2.08%). Mean value is 0.571 ± 0.051 µm2 / 38.3 ± 3.4% for males and 0.849 ± 0.091 µm2/38.3 ± 3.4% for females treated with Ibo. b Quantiﬁcation
of CATHEPSIN B (CTSB)-positive dots (in red) per neuron ((RNA Binding Protein, Fox-1 Homolog 3) RBFOX3/NeuN (in green)) conﬁrms an increase
not only in the number (number of dots: vehM+F: 0.047 ± 0.003, IboM+F: 0.153 ± 0.004, IboM: 0.153 ± 0.005, IboF: 0.153 ± 0.007/neurons/µm
2) but
also in the size of lysosome (mean dot area: vehM+F: 0.146 ± 0.009, IboM+F: 0.460 ± 0.020 µm
2, IboM: 0.490 ± 0.025 µm
2, IboF: 0.343 ± 0.021 µm
2;
dots > 0.5 µm2: vehM+F: 3.033 ± 0.723%, IboM+F: 26.10 ± 1.274%, IboM: 26.8 ± 1.3%, IboF: 18.6 ± 2.1%). Scale bars: 20 µm. Values are mean ± SEM,
*p < 0.05; **p < 0.01; ***p < 0.001. (veh: n= 63 females, 30 males; Ibo: n= 35 females, 140 males). Males are represented by black triangles and
females by white circles
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36% in 3-MA-treated rats compared to saline-injected
rats (Fig. 4a). Moreover, SQSTM1 expression levels
were also signiﬁcantly increased by 26% with 3-MA
treatment conﬁrming an efﬁcient inhibition of autophagy
by 3-MA (Fig. 4a). We then evaluated the effect of
autophagy inhibition on cell death markers at 24 h.
The expression levels of both the 150–145 kDa SPTAN
fragment and cleaved CASP3 were signiﬁcantly decreased
by 64 and 62% respectively with 3-MA treatment (Fig. 4b)
demonstrating that autophagy inhibition by 3-MA
could be neuroprotective 24 h after the induction of the
excitotoxic brain lesion. Moreover 3-MA treatment was
as efﬁcient in females as well as in males.
Long term ibotenate-induced brain damage is strongly
reduced by pharmacological inhibition of autophagy
We then evaluated the long term beneﬁt of 3-MA-
mediated autophagy inhibition on brain injury at P21
(16 days after ibotenate injection). As shown in Figs. 5a, 3-
MA treated-brains were less sensitive to ibotenate-
induced damage. The ventricle enlargement of ~20 fold
produced by ibotenate injection was strongly prevented by
Fig. 4 Ibotenate induced-autophagy and cell death is reduced by pharmacological inhibition of autophagy. a Intracerebroventricular
injection of the autophagy inhibitor 3-methyladenine (3-MA) just before ibotenate (Ibo) treatment decreases LC3-II (Ibo+ 3-MA: 64.1 ± 5.3%) and
increases SQSTM1 (Ibo+ 3-MA: 126.5 ± 4.6%) levels 24 h after Ibo injection compared to rat pups treated with saline (Ibo+ saline: LC3, 100 ± 3.5%;
SQSTM1, 100 ± 3.5%) as shown by representative immunoblots of cortical extracts and the corresponding quantiﬁcations. Mean LC3-II value is 55.6 ±
6.7% for males and 71.5 ± 7.7% for females at 24 h. Mean SQSTM1 value is 127.4 ± 7.2% for males and 127.5 ± 7.07% for females at 24 h. b 3-MA
prevents both 150–145 kDa calpain-dependent cleavage of spectrin/fodrin (SPTAN) (Ibo+ saline: 100 ± 8.8%, Ibo+ 3-MA: 51.5 ± 12.9%) and those of
caspase-3 (CASP3) (Ibo+ saline: 100 ± 9.1%, Ibo+ 3-MA: 55.8 ± 14.4%). Mean SPTAN value is 21.7 ± 4.3% for males and 52.7 ± 12.9% for females at
24 h. Mean CASP3 value is 25.8 ± 6.1% for males and 44.8 ± 13.7% for females at 24 h. Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001. (Ibo
+ saline: n= 15 females, 10 males; Ibo+ 3-MA: n= 16 females, 14 males). Males are represented by black triangles and females by white circles
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Fig. 5 Long term ibotenate-induced brain damage is strongly reduced by pharmacological inhibition of autophagy. a Representative cresyl
violet-stained coronal sections of brain 16 days (P21) after injury illustrating the protective effect of the autophagy inhibitor 3-methyladenine (3-MA)
injected in the ipsilateral ventricle just before ibotenate (Ibo). Scale bar: 1 mm. b 3-MA treatment reduces Ibo-induced ventricle dilatation (veh+
saline: 0.386 ± 0.086%, Ibo+ saline: 7.655 ± 1.233%, Ibo+ 3-MA: 0.646 ± 0.112%, veh+ 3MA: 0.366 ± 0.056%). Mean values for Ibo+ saline treatment
are 6.88 ± 1.38% for males and 8.10 ± 1.79% for females whereas those for Ibo+ 3-MA are 0.53 ± 0.16% for males and 0.78 ± 0.21% for females.
c Quantiﬁcation of ipsilateral surviving tissue volume (veh+ saline: 49.94 ± 0.167%, Ibo+ saline: 41.41 ± 1.486%, Ibo+ 3-MA: 49.22 ± 0.379%, veh+
3MA: 49.43 ± 0.428%) relatively to total brain volume and more speciﬁcally those of the ipsilateral cortex (veh+ saline: 24.09 ± 0.258%, Ibo+ saline:
18.76 ± 0.926%, Ibo+ 3-MA: 23.13 ± 0.329%, veh+ 3MA: 23.78 ± 0.170%) shows that Ibo-induced decrease in brain tissue volume is prevented by
3-MA. Mean surviving tissue volumes for Ibo+ saline treatment are 42.11 ± 1.68% for males and 41.02 ± 2.16% for females whereas those for Ibo+
3-MA are 49.92 ± 0.34% for males and 48.45 ± 0.59% for females. d. 3-MA attenuates the Ibo-induced decrease in the thickness of white matter
located at three different levels: corpus callosum (veh+ saline: 452.61 ± 17.16 µm, Ibo+ saline: 394.72 ± 28.76 µm, Ibo+ 3-MA: 490.73 ± 11.08 µm,
veh+ 3MA: 433.67 ± 19.19 µm), cingulum region (veh+ saline: 617.54 ± 21.96 µm, Ibo+ saline: 369.76 ± 37.63 µm, Ibo+ 3-MA: 560.37 ± 35.46 µm,
veh+ 3MA: 592.40 ± 37.53 µm) and at the beginning of the external capsule (veh+ saline: 337.89 ± 18.44 µm, Ibo+ saline: 269.80 ± 16.23 µm, Ibo+
3-MA: 358.28 ± 19.20 µm, veh+ 3MA: 338.05 ± 24.81 µm). 3-MA tends to have a similar protective effect on white matter thickness in males and
females. Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001. (veh+ saline: n= 6 females, 5 males, Ibo+ saline: n= 16 females, 9 males, Ibo+
3-MA: n= 8 females, 9 males, veh+ 3MA: n= 3 females, 3 males). Males are represented by black triangles and females by white circles
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3-MA treatment (reduced to only 1.7 fold) (Fig. 5b).
Moreover, ibotenate-induced tissue loss of 8.54% (total
ipsilateral WM and GM), with a decrease of 5.33%
speciﬁcally for cortex (total ipsilateral intact cortex), was
also, on average, signiﬁcantly prevented in 3-MA-treated
rats compared to saline-treated rats (Fig. 5c).
To evaluate the effect of ibotenate on WM, the thick-
ness of the subcortical WM was measured at three dif-
ferent levels around the ibotenate injection site. Reduced
thickness could reﬂect an indirect effect of the GM lesion
with secondary axonal degeneration and/or a direct
excitotoxic effect on immature oligodendrocytes. A sig-
niﬁcant decrease in the thickness of subcortical WM of
13% for corpus callosum, 40% for the WM located at the
level of cingulum and 20% for external capsule was
detected in ibotenate-treated brains (Fig. 5d). These WM
alterations were not observed when 3-MA was co-injected
with ibotenate (Fig. 5d).
Taken together, these data showed a long term bene-
ﬁcial effect of pharmacological autophagy inhibition
against ibotenate-induced brain damage that was more-
over observed both in males and females.
An excitotoxic dose of ibotenate enhances autophagic ﬂux
in primary cortical neuronal cultures
In order to conﬁrm that ibotenate could enhance
autophagy and that speciﬁc autophagy inhibition could be
neuroprotective against ibotenate-mediated excitotoxi-
city, we then decided to evaluate the effect of an excito-
toxic dose of ibotenate on autophagy in primary cortical
neuronal cultures. In general, 50 µM of ibotenate pro-
moted neuronal death as suggested by a 3 and 14 fold
increase in lactate deshydrogenase (LDH) release in the
culture medium 3 and 6 h, respectively after ibotenate
treatment (Fig. 6a). This LDH release was abolished by
MK801 or EGTA pretreatment (data not shown) con-
ﬁrming excitotoxic mechanisms (NMDA receptors over-
activation and calcium overload).
As shown in Fig. 6b, activation of autophagy occurred
along with neuronal death since both LC3-II expression
and SQSTM1 degradation were increased at 3 and 6 h. In
order to conﬁrm an enhanced autophagic ﬂux, ibotenate
was ﬁrst applied in the presence of lysosomal enzymes
inhibitors (Fig. 6c). A combination of E64 and pepstatin
A1 (PepA) (10 μg/ml) induced an accumulation of both
LC3-II (of 123%) and SQSTM1 (of 13%) reﬂecting the
failure in the autophagy degradation step. When ibotenate
was applied 4 h after E64/PepA, LC3-II and SQSTM1
accumulations were even greater (174 and 21% respec-
tively), demonstrating that ibotenate treatment triggered
the new formation of autophagosomes and thus con-
ﬁrming that ibotenate treatment increased the autopha-
gosome biogenesis. Second, autophagic ﬂux was
monitored using the tandem mRFP-GFP-LC3 plasmid
that allows to discriminate between LC3 expressed in
neutral compartments (GFP+ RFP+; early autophago-
somes: i.e. autophagosomes before fusion with lysosomes)
and in acidic vesicles (GFP-RFP+; i.e., late autophago-
somes: autophagosomes after fusion with lysosomes
(autolysosomes)) thanks to the pH sensitivity differences
exhibited by the two ﬂuorescent proteins (Fig. 6e). A
quantiﬁcation of the different LC3-positive dots per
neuron per µm2 clearly demonstrated that both autop-
hagosomes formation (~5 fold increase of GFP+ RFP+
dots) and their fusion with the lysosomes (~13 fold
increase of GFP−RFP+ dots) were enhanced by ibotenate
treatment. Taken together, these results on cortical neu-
ronal cultures allow to conclude that an excitotoxic dose
of ibotenate was efﬁcient to induce a boost of neuronal
autophagic ﬂux.
Pharmacological and genetic inhibition of autophagy is
protective against ibotenate-induced excitotoxicity in
primary cortical neuronal cultures
We then assessed the functional role of the ibotenate-
enhanced autophagy in primary cortical neuronal cul-
tures. We ﬁrst used 3-MA. Pre-treatment with 3-MA (10
mM) prevented the increases in both LC3-II expression
and SQSTM1 degradation at 6 h after ibotenate treatment
(Fig. 7a). 3-MA displayed a signiﬁcant neuroprotective
effect as shown by a decrease of 26% in LDH release
(Fig. 7b). Interestingly, blocking lysosomal degradation
with E64/PepA also reduced neuronal death (Fig. 7c)
suggesting a role of autophagy degradation step in
ibotenate-induced neurotoxicity.
Then, in order to inhibit more speciﬁcally autophagy,
downregulation of the expression of two important
autophagy proteins (ATG7 and BECLIN1 (BECN1)) was
performed using lentiviral vectors transducing short
hairpin RNAs (shRNAs) (Fig. 8a). Transduction of cul-
tured primary cortical neurons with Atg7 and Becn1
shRNAs resulted in an efﬁcient inhibition of autophagy as
demonstrated by a decrease in both LC3-II expression and
SQSTM1 degradation (Figs. 8b, c). The death-promoting
role of enhanced autophagy in ibotenate-induced neuro-
nal death was conﬁrmed by a reduction of ~30% of LDH
release when ATG7 and BECN1 were downregulated
(Fig. 8d).
In conclusion, these in vitro data conﬁrmed that an
excitotoxic dose of ibotenate could induce autophagy-
mediated neuronal death and that targeting autophagy
inhibition could lead to neuroprotection.
Discussion
In the present study, we investigated for the ﬁrst time
the role of autophagy in a preclinical model of premature
brain damage related to cPVL42. The effect of ibotenate
injection on rodent brain development is highly
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Fig. 6 Excitotoxic dose of ibotenate enhances autophagic ﬂux in primary cortical neuronal cultures. a Ibotenate (Ibo, 50 µM) is neurotoxic as
shown by lactate deshydrogenase (LDH) release in the culture medium of cultured neurons (veh: 7.4 ± 1.1%, 1h30: 6.4 ± 0.9%, 3 h: 21 ± 1.9%, 6 h: 100
± 3.2%). b Representative immunoblots and the corresponding quantiﬁcations demonstrate an increase in LC3-II (veh: 100 ± 2.7%, 1h30: 110.4 ± 4.6%,
3 h: 132.3 ± 8.5%, 6 h: 147.6 ± 6.6%) and a decrease in SQSTM1 (veh: 100 ± 1.5%, 1h30: 89.7 ± 3.3%, 3 h: 88.1 ± 4.4%, 6 h: 84.2 ± 4.4%) level of expression
following Ibo treatment. c Addition of pepstatin A (PepA) and E64 prevents lysosomal degradation as shown by increases in the level of LC3-II (veh
Pep/E64: 223.2 ± 14.3%) and SQSTM1 (veh Pep/E64: 113 ± 2.8%) relative to neurons treated with DMSO (veh DMSO; LC3-II: 100 ± 3.3%, SQSTM1: 100 ±
2.6%). When added 4 h before Ibo (3 h), PepA/E64 treatment results in a greater increase in LC3-II (Ibo E64/PepA: 274.1 ± 19.9%) than treatment with
E64/PepA or Ibo alone (Ibo DMSO: 148.7 ± 6.7%). E64/PepA pretreatment inhibits the Ibo-induced degradation of SQSTM1 (Ibo DMSO: 84.4 ± 2.2%;
Ibo E64/PepA: 120.8 ± 5.5%). d Representative confocal images of cultured neurons transfected with the tandem mRFP-GFP-LC3–expressing plasmid
6 h after Ibo addition. Quantiﬁcation of the number of LC3-positive dots per neuron per µm2 demonstrates an enhanced functional autophagic ﬂux
(Total= GFP+ RFP+ and GFP−RFP+ : veh: 0.024 ± 0.003, Ibo: 0.174 ± 0.016; GFP+ RFP+ (early autophagosomes): veh: 0.015 ± 0.002, Ibo: 0.076 ±
0.007; GFP−RFP+ (autolysosomes) veh: 0.008 ± 0.001, Ibo: 0.100 ± 0.011). Scale bar: 10 µm.Values are mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001
Descloux et al. Cell Death and Disease  (2018) 9:853  Page 9 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
dependent of the age. If injected around P5, when neu-
ronal migration is completed, the model mimics some of
the preterm brain injury features42. Human preterm WM
injury is often observed with GM developmental altera-
tion and/or damage (neuronal-axonal disease)2,3,16,17,44.
Persistent cerebral volume reduction and ven-
triculomegaly are also observed in premature infants
compared to full-term45,46. The injection of ibotenate
in the subcortical WM at the level of the right cingulum
caused a severe lesion in rat pups and led to reduced
subcortical WM thickness, signiﬁcant loss of tissue and
important lateral ventricle enlargement 16 days after
injury. It has been shown that excitotoxicity-induced
inﬂammation through microglial release of cytokines
and free radicals played a central deleterious role47,48 and
that apoptotic pathways were implicated in similar
models of preterm brain injury49,50. However, autophagy-
mediated neuronal death has never been investigated in
this context.
Macroautophagy is an important physiological
mechanism of degradation present at a basal level com-
plementary to the proteasome system. A “controlled”
upregulation of autophagy has been considered for a long
time as a survival response, for instance, acting as an
alternative source of energy during starvation or as
a quality control step eliminating toxic metabolites,
defective organelles or intracellular pathogens23,51,52.
However, this dogma has been challenged about 30 years
ago by the description of dying cells without typical
morphological hallmarks of apoptosis or necrosis and
containing numerous autolysosomes27. This new mor-
phological type of cell death was coined “autophagic cell
death” and the missuse of the term led to a strong debate
on a possible pro-death role of autophagy in some stress
Fig. 7 Pharmacological inhibition of autophagy is protective against ibotenate-induced excitotoxicity in primary cortical neuronal
cultures. a Pretreatment with 3-methyadenine (3-MA) 1 h before ibotenate (Ibo) addition for 6 h prevents LC3-II increase (veh: 100 ± 5%; Ibo: 143.7 ±
7.8%; veh+ 3-MA: 64.6 ± 3.4%; Ibo+ 3-MA: 106.1 ± 6.7%) and SQSTM1 decrease (veh: 100 ± 1.4%; Ibo: 78.4 ± 3.4%; veh+ 3-MA: 131 ± 8.2%; Ibo+ 3-
MA: 104.3 ± 7.1%) induced by Ibo as shown by representative immunoblots and the corresponding quantiﬁcations. b 3-MA decreases neuronal death
as shown by reduced lactate deshydrogenase (LDH) release in the culture medium of cultured neurons (veh: 10 ± 1.7%; Ibo: 100 ± 4.3%; veh+ 3-MA:
8.6 ± 1.4%; Ibo+ 3-MA: 74.7 ± 7.5%). c E64/PepA pretreatment reduces neuronal death as indicated by a decrease in LDH release measured 6 h after
Ibo addition (veh DMSO: 16.8 ± 2.9; Ibo DMSO: 100 ± 5%; veh E64/PepA: 21.3 ± 5.8%; Ibo E64/PepA: 69.6 ± 9.7%). Values are mean ± SEM, *p < 0.05;
**p < 0.01; ***p < 0.001
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conditions10,34,35. In fact, “autophagic cell death” is a
distinct mechanism of cell death independent of apoptotic
and necrotic machinery that is observed in some speciﬁc
circumstances27,38,53. However, there is now evidences
and it is well accepted, that autophagy can be more fre-
quently involved in cell death as a trigger leading to
Fig. 8 Genetic inhibition of autophagy is protective against ibotenate-induced excitotoxicity in primary cortical neuronal cultures.
a Lentiviral transduction of shRNA directed against BECLIN1 (BECN1) (sc shRNA: 100 ± 1.9%; Becn1 shRNA: 43 ± 12.3%) and ATG7 (sc shRNA: 100 ±
7.4%; Atg7 shRNA: 63 ± 10.9%) proteins efﬁciently reduced the expression of both proteins. b, c Downregulation of both (b) BECN1 and (c) ATG7
prevents LC3-II increase ((b) veh sc shRNA: 100 ± 2.1%; Ibo sc shRNA: 135 ± 9.4%; veh Atg7 shRNA: 64.4 ± 9.1%; Ibo Atg7 shRNA: 60.8 ± 6.6%; (c) veh sc
shRNA: 100 ± 1.8%; Ibo sc shRNA: 125.6 ± 5.5%; veh Becn1 shRNA: 98.4 ± 4.6%; Ibo Becn1 shRNA: 100.6 ± 4.1%) and SQSTM1 decrease ((b) veh sc
shRNA: 100 ± 1.4 %; Ibo sc shRNA: 93 ± 3.4%; veh Atg7 shRNA: 109.5 ± 4%; Ibo Atg7 shRNA: 117.2 ± 3.6%; (c) veh sc shRNA: 100 ± 1.4%; Ibo sc shRNA:
91.3 ± 3.2%; veh Becn1 shRNA: 132.4 ± 19.3%; Ibo Becn1 shRNA: 119.4 ± 10.7%) induced by Ibo (6 h) as shown by representative immunoblots and
the corresponding quantiﬁcations. d Downregulation of both ATG7 and BECN1 has a neuroprotective effect as demonstrated by reduced
lactate deshydrogenase (LDH) release in the culture medium of cultured neurons (veh sc shRNA: 7.2 ± 1.4 %; veh Atg7 shRNA: 11.3 ± 1.9%; veh Becn1
shRNA: 15.9 ± 3%; Ibo sc shRNA: 100 ± 7%; Ibo Atg7 shRNA: 71.4 ± 6.3%; Ibo Becn1 shRNA: 68.8 ± 7%). Values are mean ± SEM, *p < 0.05; **p < 0.01;
***p < 0.001
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apoptotic or necrotic cell death (autophagy-mediated
cell death)20,21,29,34,38,54–57. Excitotoxicity and cerebral
HI are some of the conditions where autophagy is
enhanced58. Although some controversies exist32,33,59,
most of the studies using pharmacological inhibitors
such as 3-MA30,37 and especially those using speciﬁc and
genetic inhibition of atg20,29,31 revealed a deleterious
role of autophagy. They also supported the concept of a
strong interconnection between autophagic and apoptotic
mechanisms in perinatal cerebral HI19,20,32,60. The present
study is the ﬁrst to demonstrate a death-promoting role of
autophagy in a preterm model of excitotoxic brain lesion.
Our results strongly suggest that autophagy is enhanced
in neurons after ibotenate injection in the brain of rat
pups, as also demonstrated in primary cortical neurons
cultures. Autophagosome formation is increased from 6 h
as shown by a higher level of LC3-II and more LC3-
positive dots. This increase was not due to impaired
autophagosome degradation that would have occurred if
lysosomal function was defective. In fact, p62/SQSTM1
is also degraded and autolysosomes are increased in
neurons as indicated by larger and more numerous
LAMP1- and CTSB-positive dots. This result is consistent
with EM observations showing the presence of both
autophagosome-like multimembrane vesicles and
autolysosome-like dense structures in dying neurons of
ibotenate-injected rat pups. We provide here, especially in
primary neuronal cultures, compiling evidences demon-
strating that the autophagy ﬂux is increased by ibotenate
treatment. Both Western blots against LC3 and p62/
SQSTM1 with or without E64/pepstatinA co-treatments
and the use of the GFP-RFP-LC3 construct lead to the
same conclusion, ibotenate treatment is increasing
autophagosome formation and degradation. Moreover,
the GFP-RFP-LC3 construct we used is less sensitive to
acidiﬁcation comparing to other constructs, such as
the mKate2-pHluorin-hLC361, suggesting that the num-
ber of autolysosomes could be theoretically under-
estimated. Our in vitro data on primary cortical neuronal
cultures also strongly argued for the induction of an
autophagy-mediated neuronal death by ibotenate. Inhi-
bition of autophagy, not only pharmacologically with
3-MA or E64/PepA, but also genetically by down-
regulating two important ATG proteins, ATG7 or
BECN1, was neuroprotective as previously shown when
excitotoxicity was induced in hypoxic conditions29.
Even if caution is necessary concerning the limited
speciﬁcity of 3-MA as an autophagy inhibitor22, we here
clearly showed that the dose used in vivo efﬁciently
prevented autophagy (decrease in LC3-II level and
SQSTM1/p62 degradation). Furthermore, since it is
known that permanent impaired autophagy leads to
neurodegeneration (as it would be the case with long term
genetic inhibition of autophagy)43, the use of 3-MA was
appropriate to study long term effect on brain lesion
in vivo (16 days after the insult). When ibotenate-
enhanced autophagy was prevented by 3-MA treatment,
both CASP3 activation and calpain-dependent cleavage of
SPTAN (used as an indicator of necrotic cell death
characterized by a calcium increase) were signiﬁcantly
decreased. Moreover, ultrastructural observations showed
condensed chromatin in nuclei of dying and highly
autophagic neurons. Mixed features of apoptosis and
autophagy were also observed in rodent models of peri-
natal cerebral HI19,20,30,31,60 and we previously demon-
strated that autophagy could contribute to apoptosis
using widely recognized apoptotic stimuli in primary
cortical neuron cultures62. The beneﬁcial effect of 3-MA
on neuronal cell death, including apoptosis, resulted here
in a strong signiﬁcant neuroprotective effect at long term
on both GM and WM, suggesting a crucial role of
autophagy in mediating (apoptotic and necrotic) cell
death. Studies on perinatal cerebral HI models have also
shown that autophagy inhibition could be neuroprotective
and reduce apoptosis20,30,31 suggesting that the transient
inhibition of autophagy could be a promising strategy to
protect the immature brain against excitotoxic insults.
It has been shown that females are more resistant to
perinatal cerebral injury than males, especially in the
context of cerebral HI and after moderate lesions, in
rodents as well as in humans63–66. The reason of this
gender difference is still unclear, but sex-dependent cell
death pathways have been recognized after perinatal
cerebral HI, especially more active caspase-dependent
pathways in females66–68. In the present study, we also
found a stronger CASP3 activation and a more important
variability in females in almost all the different parameters
investigated. However, mean ibotenate-induced brain
lesion volume was similar in both genders. Moreover, the
protective effect of 3-MA against both ibotenate-induced
autophagy and cerebral lesions was as efﬁcient in males as
in females.
In conclusion, we showed for the ﬁrst time that
enhanced autophagy could mediate cell death in a pre-
mature model of excitotoxic brain damage. Autophagy
inhibition in this severe model is very promising since the
protective effect obtained is similar or even better to other
previously described neuroprotectants such as caspases
inhibitors69, erythropoietin70,71, BDNF72,73, melatonin74
or magnesium sulfate75,76. Interestingly, we recently
demonstrated that autophagy is enhanced in dying neu-
rons in the ventrolateral nucleus of the thalamus and the
lentiform nucleus of term newborns with severe HIE31,60.
Apoptotic markers were also expressed in dying highly
autophagic neurons, arguing for a possible association
between autophagy and apoptosis also in humans.
Moreover an increased presence of autophagosomes
(LC3-positive dots) was recently demonstrated in WM
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injury of extremely preterm infants77. These 3 different
studies using human newborn brain sections31,60,77 and
the important neuroprotection obtained with 3-MA in
the present study in a severe model of cPVL suggest
that enhanced neuronal autophagy could be a promising
target. The development of strategies transiently inhibit-
ing autophagy could pave the way for new therapies
against neonatal severe excitotoxic injuries such as HIE
and cPVL.
Material and methods
Primary cortical neuronal cultures
Primary neuronal cultures were prepared according
to the Swiss laws for the protection of animals from
pieces of cortices of 2-day-old Sprague-Dawley rat pups
(Janvier Labs, Mayenne, France). The procedures were
approved by the Vaud Cantonal Veterinary Ofﬁce.
After dissection, dissociation and trituration, neurons
were plated in neurobasal medium (Gibco, NY, USA;
21103–049) supplemented with 2% B27 (Gibco;
17504044), 0.5 mM L-glutamine (Sigma, MO, USA;
49419) and 100 μg/ml penicillin-streptomycin (Gibco;
15140122) and maintained at 37 °C with a 5% CO2-con-
taining atmosphere as described previously78. Western
blot analyses were done on neurons plated at a density
of ~7 × 105 cells/dish (35-mm poly-D-lysine pre-coated
dishes (BD Biosciences, NJ, USA; 356467) and at a
density of ~3 × 105 cells on 12-mm glass coverslips coated
with 0.01% poly-L-lysine (Sigma; P4832) for immunocy-
tochemistry and imaging. For all the Western blots or
imaging results, at least three independent experiments,
each involving two or three culture dishes or coverslips,
were performed.
Pharmacological treatments
Primary cortical neuronal cultures were pre-treated for
1 h with 10mM 3-methyladenine (3-MA) (Sigma;
M9281), 5 mM EGTA (Sigma; E0396) or 40 μM MK801
(Sigma; M107). For inhibition of lysosomal degradation, a
cocktail of 10 μg/ml pepstatin A1 (PepA) (Sigma; P5318)
and 10 μg/ml E64 (Sigma; E3132) was applied for 4 h prior
to 50 μM ibotenic acid (Enzo Life Sciences, NY, USA;
BML-EA120–0001) addition.
Quantiﬁcation of cell death with lactate dehydrogenase
release
Cell death was assayed by measurement of LDH
released in the medium using the Cytotox 96 non-
radioactive cytotoxicity assay kit (Promega, WI, USA;
G1780) as previously described78. LDH measurements
were normalized with respect to the values of ibotenate-
treated neurons 6 h after the ibotenate addition.
Knockdown of ATG using lentiviral vectors
Downregulation of Atg genes were performed with
pLKO lentiviral vectors (Open Biosystems/Dharmacon,
CO, USA) expressing rat-speciﬁc shRNA sequences
from TRC (the RNAi consortium) library as described
previously62. A combination of TRCN0000092163
and TRCN0000092166 for Atg7 (GenBankTM
NM_001012097), TRCN0000033552 for Becn1 (Gen-
BankTM NM_053739.2) and a pLKO vector containing
scrambled shRNA (Open Biosystems/Dharmacon) as
control vector were used. Primary cortical neuron cul-
tures were infected at DIV7 with 50 ng of the viral capsid
protein p24/ml culture medium for each vector.
mRFP-GFP-LC3 plasmid transfection and quantiﬁcation
Neurons on coverslips were transfected with the tan-
dem mRFP-GFP-LC3–expressing plasmid ptfLC3
(Addgene, MA, USA; 21074)79 using Lipofectamine 2000
(Invitrogen, CA, USA; 11668-019) as described pre-
viously29. Coverslips were ﬁxed with 4% paraformalde-
hyde for 15 min. Confocal images were acquired using a
Zeiss LSM 710 Meta confocal laser scanning microscope.
Total LC3-positive dots (GFP+ RFP+ and GFP− RFP+
dots), early autophagosomes (GFP+ RFP+ dots) and
mature or late autophagosomes (GFP− RFP+ dots) were
analyzed using ImageJ software and expressed as a num-
ber of positive dots per neuron per µm2.
Rat model of preterm excitotoxic brain injury
All experiments were performed in accordance with the
Swiss laws for the protection of animals and were
approved by the Vaud Cantonal Veterinary Ofﬁce. Ten µg
of ibotenate (diluted 5 µg/µl in acetic acid 0.02%) were
stereotaxically injected under isoﬂurane anesthesia (2.5%)
in the subcortical WM at the level of the right cingulum
(1 mm posterior and 1mm right from Bregma and
1.5 mm depth from the skull surface) of 5-day-old male
and female Sprague Dawley rats (Janvier Labs) (model
adapted from Marret and colleagues (1995)42). The con-
trol animals received an injection of the same volume of
vehicle (acetic acid 0.02%). The pharmacological autop-
hagy inhibitor 3-MA (2 µl of 30 mg/ml in saline) was
stereotaxically injected in the right lateral ventricle
(0.5 mm posterior and 1mm right from Bregma and
2.5 mm depth from the skull surface) just before ibotenate
injection. Control animals received an injection of the
same volume of saline as vehicle. After recovering from
anesthesia, rat pups returned to the dam until sacriﬁce.
Electron microscopy
Electron microscopy (EM) was done on rat brains ﬁxed
following intracardiac perfusion with 2.5% glutaraldehyde
and 2% paraformaldehyde in cacodylate buffer (0.1 M,
pH7.4) as previously described80.
Descloux et al. Cell Death and Disease  (2018) 9:853  Page 13 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
Immunoblotting
Immunoblots were performed on extracts from primary
neuronal cultures or from cortex collected in lysis buffer
(20mM HEPES, pH 7.4, 10mM NaCl, 3 mM MgCl2,
2.5mM EGTA, 0.1mM dithiothreitol, 50mM NaF, 1mM
Na3VO4, 1% Triton X-100 and a protease inhibitor cock-
tail (Sigma;11873580001)29. Protein concentration was
determined using a Bradford assay. Proteins (20–40 µg)
were separated on 10, 12 or 15% polyacrylamide gels and
analyzed by immunoblotting. Antibodies were diluted in
the blocking solution containing 0.1% casein (Sigma;
C8654). Primary antibodies used were: anti-ATG7
(sc-33211) rabbit polyclonal and anti-BECN1 (sc-11427)
rabbit polyclonal from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); anti-LC3 (ab48394) rabbit polyclonal
from Abcam (MA, USA); anti-cleaved CASP3/caspase-3
(9661) rabbit polyclonal from Cell Signalling Technology
(MA; USA); anti-SQSTM1 (P0067) rabbit polyclonal
from Sigma; anti-FODRIN/SPECTRIN (FG6090) mouse
monoclonal from Enzo Life Sciences and anti-ACTA/α-
ACTIN (MAB1501) mouse monoclonal from Millipore/
Merck (MA, USA). Secondary antibodies were polyclonal
goat anti-mouse or anti-rabbit IgG from LiCOR (IRDye
680 or IRDye 800). Protein bands were visualized with
the Odyssey Infrared Imaging System (LICOR, NE, USA).
Odyssey v1.2 software (LICOR) was used for analysis.
Values were normalized with respect to ACTIN.
Immunohistochemistry
Immunostainings were performed on 20μm cryostat
brain sections from rat pups perfused transcardially with
4% paraformaldehyde in 0.1 mol/L PBS (pH 7.4)29. PBS
with 15% donkey serum and 0.3% Triton X-100 were used
for blocking and permeabilization for 30–45min. Primary
antibodies diluted in PBS with 1.5% donkey serum and
0.1% Triton X-100 overnight at 4 °C were: anti-cleaved
CASP3/caspase-3 (9661) rabbit polyclonal from Cell
Signalling Technology; anti-LC3 (ab48394) rabbit poly-
clonal from Abcam; anti-CTSB/cathepsin B (06–480),
anti-MAP2 (AB5622) rabbit polyclonal antibodies, anti-
RBFOX3/NeuN (MAB377) and anti-LAMP1 (428017)
mouse monoclonal antibodies from Merk/Millipore.
Secondary antibodies were diluted in PBS for 2 h at room
temperature.
For immunoﬂuorescence labeling, Alexa Fluor donkey-
anti-rabbit or mouse secondary antibodies (Invitrogen;
A21202, A21203, A21206, A21207) were used. A LSM
710 Meta confocal microscope (Carl Zeiss) were used for
confocal laser microscopy. Images were processed with
LSM 510 software and mounted using Adobe Photoshop.
Quantiﬁcation of autophagic and lysosomal labeling
Confocal images of ﬂuorescent immunostaining against
LC3, CTSB and LAMP1 were acquired using the LSM 710
Meta confocal laser scanning microscope (Carl Zeiss) and
images were then processed with Adobe Photoshop CC
2015. Positive dots were quantiﬁed using ImageJ software
and expressed as a number of positive dots per neuron
per μm2 and, for the lysosomal markers CTSB and
LAMP1, as a mean dot area per neuron per μm2.
Cerebral regions volume and WM thickness measurements
Sixteen days after the injury (at P21) brains were per-
fused, frozen and entirely cut into series of 20 μm coronal
sections spaced at 500μm disposed in series. On a cresyl
violet-stained series, the ipsilateral volume of the total
surviving tissue, the cortex and the lateral ventricle were
measured using the Zen Blue software (Zeiss). The
volumes were then expressed as a percentage of the total
brain volume.
WM thickness were measured on 3 consecutive cresyl
violet-stained sections starting from the ﬁrst on which
the genu of the corpus callosum appeared (approx.
0.6–0.8mm anterior to the Bregma according to the
“atlas of the rat brain in stereotaxic coordinates at P21” of
Khazipov et al., http://www.ialdevelopmentalneurobiology.
com/images/atlases/Atlas-p21.pdf81). The thickness of the
ipsilateral corpus callosum (on the midline) and the sub-
cortical WM at the level of the cingulum (1.4 mm apart
from the midline) and at the beginning of the external
capsule (2mm apart from the midline) were measured
parallel to the midline with the Zen Blue software (Zeiss).
Values are expressed as a mean of the three measures.
Statistics
Values were expressed as mean values ± standard error
of the mean (SEM). Data were analyzed statistically using
GraphPad PRISM (version 7.03) software. The normality
of the distribution was ﬁrst tested using Shapiro–Wilk
tests. Parametric data were analyzed using a Welch’s
ANOVA test (one-way ANOVA with unequal variances)
followed by a post-hoc Tukey-Kramer test. Non-
parametric data were analyzed using a Kruskal–Wallis
test (non-parametric analog of the one-way ANOVA)
followed by a post-hoc Steel-Dwass. P < 0.05 was chosen
as threshold for statistical signiﬁcance.
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